[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1983
1. Pawlikowski M, Kunert-Radek J, Radek M: Plurihormonality of pituitary adenomas in light of immunohistochemical studies. Endokrynol Pol; 2010 Jan-Feb;61(1):63-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plurihormonality of pituitary adenomas in light of immunohistochemical studies.
  • INTRODUCTION: Plurihormonality of pituitary adenomas can be defined as the ability of an adenoma to express more than one pituitary hormone.
  • The application of immunohistochemistry to diagnose surgically removed pituitary tumours revealed that a great number of pituitary adenomas are in fact plurihormonal.
  • However, data on the incidence and the clinical relevance of the pituitary adenoma plurihormonality are still scarce and controversial.
  • MATERIAL AND METHODS: Hundred fifty-five pituitary adenomas, surgically removed, were studied immunohistochemically with the antibodies against pituitary hormones or their subunits.
  • Additionally, 40 adenomas were immunostained with Ki-67 antibody to evaluate the proliferative potential.
  • Even with this limitation, plurihormonality was found to be a frequent finding in both hormonally active and clinically non-functioning pituitary adenomas.
  • It was shown that over one-third (36.1%) of the investigated adenomas expressed more than one hormone.
  • Plurihormonal adenomas also possess higher Ki-67 indices, as compared to monohormonal tumours.
  • CONCLUSIONS: Plurihormonality is a frequent phenomenon in both hormonally active and clinically non-functioning pituitary adenomas.
  • [MeSH-major] Adenoma / metabolism. Neoplasm Recurrence, Local / metabolism. Pituitary Hormones / metabolism. Pituitary Neoplasms / metabolism
  • [MeSH-minor] Adrenocorticotropic Hormone / metabolism. Follicle Stimulating Hormone / metabolism. Human Growth Hormone / metabolism. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Luteinizing Hormone / metabolism. Pituitary ACTH Hypersecretion / complications. Pituitary ACTH Hypersecretion / metabolism. Prolactin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205106.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Pituitary Hormones; 12629-01-5 / Human Growth Hormone; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


2. Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Klibanski A: Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology; 2010 Mar;151(3):939-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Maternally expressed gene 3 (MEG3) is an imprinted gene highly expressed in the human pituitary.
  • However, MEG3 expression is lost in human gonadotroph-derived pituitary adenomas and most human tumor cell lines.

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Cells. 2000 Mar;5(3):211-20 [10759892.001]
  • [Cites] Mamm Genome. 2003 Apr;14(4):231-41 [12682775.001]
  • [Cites] Curr Biol. 2000 Sep 21;10(18):1135-8 [10996796.001]
  • [Cites] Hum Mol Genet. 2002 Jan 1;11(1):77-86 [11773001.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1262-7 [11889197.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):222-8 [12110898.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16081-6 [12444263.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):462-70 [12403781.001]
  • [Cites] Nucleic Acids Res. 2003 Jul 1;31(13):3406-15 [12824337.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5119-26 [14602737.001]
  • [Cites] Mamm Genome. 1996 Jan;7(1):20-4 [8903723.001]
  • [Cites] Dev Dyn. 1998 Jun;212(2):214-28 [9626496.001]
  • [Cites] J Mol Biol. 1999 May 21;288(5):911-40 [10329189.001]
  • [Cites] Dev Biol. 2007 Jun 15;306(2):810-23 [17449025.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):24731-42 [17569660.001]
  • [Cites] Nat Genet. 2008 Feb;40(2):237-42 [18176563.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Oct;93(10):4119-25 [18628527.001]
  • [Cites] Curr Opin Struct Biol. 2009 Jun;19(3):260-6 [19443210.001]
  • [Cites] Genes Dev. 2000 Aug 15;14(16):1997-2002 [10950864.001]
  • (PMID = 20032057.001).
  • [ISSN] 1945-7170
  • [Journal-full-title] Endocrinology
  • [ISO-abbreviation] Endocrinology
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK040947; United States / NIDDK NIH HHS / DK / R01DK40947
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / MEG3 non-coding RNA, human; 0 / Proteins; 0 / RNA, Long Noncoding; 0 / RNA, Untranslated; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2840681
  •  go-up   go-down


3. Nemergut EC, Zuo Z, Jane JA Jr, Laws ER Jr: Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg; 2005 Sep;103(3):448-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among patients with pituitary adenomas, those with Cushing's disease had an increased risk of transient (22.2%), but not persistent, DI.
  • [MeSH-minor] Adenoma / complications. Adenoma / surgery. Central Nervous System Cysts / complications. Central Nervous System Cysts / surgery. Craniopharyngioma / complications. Craniopharyngioma / surgery. Humans. Incidence. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Prognosis. Retrospective Studies. Subdural Effusion


Advertisement
4. Ruebel KH, Leontovich AA, Jin L, Stilling GA, Zhang H, Qian X, Nakamura N, Scheithauer BW, Kovacs K, Lloyd RV: Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression. Endocrine; 2006 Jun;29(3):435-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.
  • Very few of the genes that are important in pituitary tumor initiation, progression, and metastasis have been identified to date.
  • To identify potential genes that may be important in pituitary tumor progression and carcinoma development, we used Affymetrix GeneChip HGU-133A-oligonucleotide arrays, which contain more than 15,000 characterized genes from the human genome to study gene expression in an ACTH pituitary carcinoma metastatic to the liver and four pituitary adenomas.
  • Reverse-transcriptase real-time quantitative- PCR (RT-qPCR) was then used to analyze 4 nonneoplastic pituitaries, 19 adenomas, and the ACTH carcinoma.
  • A larger series of pituitary adenomas and carcinomas were also analyzed for protein expression using tissue microarrays (TMA) (n = 233) and by Western blotting (n = 18).
  • There were 4298 genes that were differentially expressed among the adenomas compared to the carcinoma, with 2057 genes overexpressed and 2241 genes underexpressed in the adenomas.
  • The beta-galactoside binding protein galactin-3 was underexpressed in some adenomas compared to the carcinomas.
  • The human achaetescute homolog-1 ASCL1 (hASH-1) gene was also underexpressed in some adenomas compared to the carcinoma.
  • ID2, which has an important role in cell development and tumorigenesis, was underexpressed in some adenomas compared to the carcinomas.
  • Transducin-like enhancer of split four/ Groucho (TLE-4) was over-expressed in adenomas compared to the ACTH carcinoma.
  • These results indicate that the LGALS3, hASH1, ID2, and TLE-4 genes may have important roles in the development of pituitary carcinomas.
  • [MeSH-major] Adenoma / genetics. Carcinoma / genetics. Gene Expression Profiling / methods. Oligonucleotide Array Sequence Analysis / methods. Pituitary Neoplasms / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / metabolism. Blotting, Western. DNA-Binding Proteins / metabolism. Follicle Stimulating Hormone / secretion. GRB2 Adaptor Protein / metabolism. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Humans. Immunohistochemistry. Inhibitor of Differentiation Protein 2 / metabolism. Luteinizing Hormone / secretion. Nuclear Proteins / metabolism. Prolactinoma / metabolism. Repressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2493-6 [8653683.001]
  • [Cites] Endocrine. 2004 Jul;24(2):141-6 [15347840.001]
  • [Cites] Am J Pathol. 1995 Sep;147(3):815-22 [7677193.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6852-7 [11724777.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5119-26 [14602737.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):54-66 [10580129.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):450-8 [15701827.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • [Cites] Biochemistry. 1994 Nov 29;33(47):14109-14 [7947821.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1217-24 [11850841.001]
  • [Cites] Am J Clin Pathol. 2004 Jul;122(1):100-5 [15272537.001]
  • [Cites] Endocr Pathol. 2003 Spring;14 (1):37-48 [12746561.001]
  • [Cites] Genes Dev. 2001 Dec 1;15(23 ):3193-207 [11731482.001]
  • [Cites] J Biol Chem. 1994 Aug 19;269(33):20807-10 [8063692.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):899-909 [10702407.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):804-12 [9024719.001]
  • [Cites] Mol Endocrinol. 2004 Oct;18(10):2583-93 [15243129.001]
  • [Cites] J Biomol Tech. 2004 Dec;15(4):276-84 [15585824.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):3089-99 [15741248.001]
  • [Cites] Cell. 1993 Nov 5;75(3):463-76 [8221886.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1136-40 [15734994.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):37-55 [15765918.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):35-53 [10580128.001]
  • [Cites] Mol Cell Biol. 2004 May;24(10):4241-54 [15121845.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2179-86 [15644399.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1262-7 [11889197.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Jul;77(1):50-5 [8100831.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Jul 15;15(14):3344-6 [15963723.001]
  • [Cites] Endocrine. 2003 Dec;22(3):285-92 [14709802.001]
  • [Cites] Gene. 2000 May 16;249(1-2):1-16 [10831834.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):222-9 [14657947.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):525-30 [12842081.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):328-41 [11414475.001]
  • [Cites] J Cell Biochem. 2005 Jul 1;95(4):670-87 [15861397.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):143-51 [15994756.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4805-8 [11108298.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2251-5 [12727847.001]
  • [Cites] J Mol Endocrinol. 2002 Feb;28(1):33-44 [11854097.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10214-22 [16288009.001]
  • [Cites] J Endocrinol Invest. 2003 Oct;26(10):957-65 [14759067.001]
  • [Cites] J Neurooncol. 2001 Sep;54(2):111-9 [11761428.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1211-6 [10728677.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):836-49 [12415254.001]
  • [Cites] Trends Cell Biol. 2003 Aug;13(8):410-8 [12888293.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5935-45 [11486032.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):21-8 [11807807.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jul;86(7):3097-107 [11443173.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Apr;78(4):842-6 [8157709.001]
  • [Cites] Neurosurgery. 2005 May;56(5):1066-74; discussion 1066-74 [15854256.001]
  • [Cites] Nucleic Acids Res. 2003 Oct 1;31(19):5676-84 [14500831.001]
  • [Cites] Perspect Dev Neurobiol. 1994;2(2):191-201 [7728503.001]
  • [Cites] Endocrinology. 2002 Feb;143(2):347-59 [11796486.001]
  • [Cites] Mol Endocrinol. 2003 Nov;17(11):2152-61 [12907761.001]
  • [Cites] Lab Invest. 2005 Apr;85(4):464-73 [15711568.001]
  • [Cites] Gastroenterology. 1998 Aug;115(2):287-96 [9679034.001]
  • [Cites] Mamm Genome. 2001 Nov;12(11):843-51 [11845287.001]
  • (PMID = 16943582.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 90249
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / GRB2 Adaptor Protein; 0 / GRB2 protein, human; 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 2; 0 / Nuclear Proteins; 0 / Repressor Proteins; 0 / TLE4 protein, human; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


5. Silberstein L, Johnston C, Bhagat A, Tibi L, Harrison J: Pituitary apoplexy during induction chemotherapy for acute myeloid leukaemia. Br J Haematol; 2008 Oct;143(2):151
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary apoplexy during induction chemotherapy for acute myeloid leukaemia.
  • [MeSH-major] Leukemia, Myeloid, Acute / pathology. Magnetic Resonance Imaging. Pituitary Apoplexy / diagnosis. Pituitary Gland / pathology
  • [MeSH-minor] Adenoma / diagnosis. Humans. Hydrocortisone / therapeutic use. Male. Middle Aged. Pituitary Neoplasms / diagnosis. Testosterone / therapeutic use

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18699855.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 3XMK78S47O / Testosterone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


6. Onofri C, Losa M, Uhl E, Stalla GK, Renner U: Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues. Exp Clin Endocrinol Diabetes; 2008 Mar;116(3):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of VEGF-C/VEGFR-3 system and lymphatic vessel extent in normal and adenomatous human pituitary tissues.
  • We assessed the expression of VEGF-C and VEGFR-3, together with blood and lymphatic vessel extents and proliferation index (PI) values, by immunohistochemistry (IHC) in 6 normal human pituitary glands and 53 pituitary adenomas of different tumour grade, on consecutive tissue sections.
  • VEGF-C was detected in around 10% of the endocrine cells in normal pituitary tissue, while this gland was devoid of lymphatic vascularization and showed very few vessels positive for VEGFR-3.
  • Concerning tumour tissue, most of the adenomas showing VEGF-C immunoreactivity (21/47) were positive in 60% of the tumour cells and the ones positive for VEGFR-3 showed a number of immunostained vessels higher than those observed in the normal pituitary.
  • Nevertheless, we observed a significant association between low expression of VEGFR-3 and low lymphatic vessel number, suggesting that VEGFR-3 might be involved in the starting of DE NOVO lymphangiogenesis in this tumour type.
  • In conclusion, the VEGF-C/VEGFR-3 system might be involved in controlling tumour angiogenesis in the pituitary adenomas lacking lymphatic vessels, but may also play a role in starting the process of tumour lymphangiogenesis.
  • [MeSH-major] Adenoma / metabolism. Lymphatic Vessels / metabolism. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor C / metabolism. Vascular Endothelial Growth Factor Receptor-2 / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205092.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


7. Schlesinger DJ, Sayer FT, Yen CP, Sheehan JP: Leksell GammaPlan version 10.0 preview: performance of the new inverse treatment planning algorithm applied to Gamma Knife surgery for pituitary adenoma. J Neurosurg; 2010 Dec;113 Suppl:144-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leksell GammaPlan version 10.0 preview: performance of the new inverse treatment planning algorithm applied to Gamma Knife surgery for pituitary adenoma.
  • METHODS: Forty-three patients with pituitary adenomas were evaluated after dose planning was performed using FP and IP treatment approaches.
  • [MeSH-major] Pituitary Neoplasms / surgery. Radiosurgery / instrumentation. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted / instrumentation

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121796.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Arnaldi G, Polenta B, Cardinaletti M, Boscaro M: Potential indications for somatostatin analogs in Cushing's syndrome. J Endocrinol Invest; 2005;28(11 Suppl International):106-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In recent years, somatostatin analogs have been proposed and used in the diagnosis and therapy in Cushing's syndrome (CS).
  • [MeSH-major] Cushing Syndrome / diagnosis. Cushing Syndrome / drug therapy. Somatostatin / analogs & derivatives
  • [MeSH-minor] Adenoma / chemistry. Adenoma / secretion. Adrenal Gland Neoplasms / chemistry. Adrenal Gland Neoplasms / secretion. Adrenocorticotropic Hormone / secretion. Animals. Humans. Hydrocortisone / blood. Octreotide / therapeutic use. Pituitary Neoplasms / chemistry. Pituitary Neoplasms / secretion. Receptors, Somatostatin / analysis. Receptors, Somatostatin / physiology

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625858.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 51110-01-1 / Somatostatin; 9002-60-2 / Adrenocorticotropic Hormone; 98H1T17066 / pasireotide; RWM8CCW8GP / Octreotide; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 53
  •  go-up   go-down


9. Dekkers OM, Neelis KJ, de Keizer RJ, Voormolen JH, Pereira AM, Romijn JA: [Nonfunctioning pituitary macroadenomas: diagnosis, treatment and follow-up]. Ned Tijdschr Geneeskd; 2008 Apr 5;152(14):792-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nonfunctioning pituitary macroadenomas: diagnosis, treatment and follow-up].
  • [Transliterated title] Niet-functionerende macroadenomen van de hypofyse: diagnostiek, behandeling en follow-up.
  • *Nonfunctioning pituitary adenomas are benign tumours characterised by the absence of hormone overproduction.
  • The main symptoms are pituitary insufficiency, visual field defects, vision impairment and headache.
  • *Because nonfunctioning adenomas can recur, lifelong follow-up after treatment is necessary.
  • *Poor quality of life has been reported in treated patients with nonfunctioning pituitary adenomas, which may be due to the intrinsic imperfections of hormonal replacement therapy.
  • [MeSH-major] Adenoma / diagnosis. Pituitary Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18491820.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 47
  •  go-up   go-down


10. Gong SP, Lü J, Song Q, Yang QY: [Visual pathway and pituitary stalk protection in pituitary tumor surgery and the clinical outcome]. Nan Fang Yi Ke Da Xue Xue Bao; 2009 Feb;29(2):305-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Visual pathway and pituitary stalk protection in pituitary tumor surgery and the clinical outcome].
  • OBJECTIVE: To investigate the association of microsurgical anatomy and growth of pituitary tumors with the recovery of visual pathway, and describe the intraoperative protection of the pituitary stalk and visual pathway.
  • METHODS: A total of 113 patients undergoing pituitary tumor surgery were retrospectively analyzed, including 102 with visual disorder and 106 with pituitary dysfunction with the tumor size ranging from 1.9 to 6.8 cm.
  • Two patients died due to hypothalamic disorder and multiple organ failure.
  • CONCLUSION: The arachnoid barrier between the pituitary tumor and visual pathway is an important structure for visual pathway protection during operation.
  • The preoperative localization and intraoperative identification of the pituitary stalk are critical for pituitary stalk protection.
  • [MeSH-major] Intraoperative Complications / prevention & control. Microsurgery / adverse effects. Pituitary Gland / pathology. Pituitary Neoplasms / surgery. Visual Pathways / pathology
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Neurosurgical Procedures / methods. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19246307.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Daly AF, Jaffrain-Rea ML, Ciccarelli A, Valdes-Socin H, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wémeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A: Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab; 2006 Sep;91(9):3316-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characterization of familial isolated pituitary adenomas.
  • CONTEXT: Familial pituitary adenomas occur rarely in the absence of multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC).
  • OBJECTIVE: Our objective was to characterize the clinical and genealogical features of non-MEN1/CNC familial isolated pituitary adenomas (FIPA).
  • RESULTS: Sixty-four FIPA families including 138 affected individuals were identified [55 prolactinomas, 47 somatotropinomas, 28 nonsecreting adenomas (NS), and eight ACTH-secreting tumors].
  • FIPA cases were younger at diagnosis than sporadic cases (P = 0.015); tumors were diagnosed earlier in the first vs. the second generation of multigenerational families.
  • Somatotropinomas occurred as isolated familial somatotropinoma cases and within heterogeneous FIPA families; isolated familial somatotropinoma cases represented 18% of FIPA cases and were younger at diagnosis than patients with sporadic somatotropinomas.
  • Familial NS cases were younger at diagnosis (P = 0.03) and had more frequently invasive tumors (P = 0.024) than sporadic cases.
  • FIPA may represent a novel endocrine neoplasia classification that requires further genetic characterization.
  • [MeSH-major] Adenoma / genetics. Adenoma / pathology. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adrenocorticotropic Hormone / secretion. Adult. Cyclic AMP-Dependent Protein Kinase RIalpha Subunit. Cyclic AMP-Dependent Protein Kinases / genetics. Female. Gonadotropins, Pituitary / metabolism. Humans. Immunohistochemistry. Male. Middle Aged. Pedigree. Pituitary Hormones, Anterior / metabolism. Prolactinoma / genetics. Prolactinoma / pathology. Retrospective Studies. Sequence Analysis, DNA


12. Kitthaweesin K, Ployprasith C: Ocular manifestations of suprasellar tumors. J Med Assoc Thai; 2008 May;91(5):711-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHOD: Medical records of 69 patients with a diagnosis of suprasellar tumor at Srinagarind Hospital between January 1995 and December 2005 were retrospectively reviewed.
  • The respective definite diagnosis were pituitary adenoma, suprasellar meningioma, and craniopharyngioma in 33 (48%), 19 (28%), and 17 (25%) patients.
  • CONCLUSION: Pituitary adenoma was the most frequent suprasellar tumor and visual loss was the most common ocular presentation.
  • [MeSH-major] Craniopharyngioma / pathology. Eye Diseases / etiology. Meningioma / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Eye Diseases.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18672637.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


13. Geiger D, Meek C, Wexler Y: Speeding up HMM algorithms for genetic linkage analysis via chain reductions of the state space. Bioinformatics; 2009 Jun 15;25(12):i196-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For a Finnish family in which two affected children suffer from a rare cold-inducing sweating syndrome, we were able to reduce the state space by more than five orders of magnitude from 2(50) to 2(32).
  • In another pedigree of state-space size of 2(27), used for a study of pituitary adenoma, the state space reduced by a factor of 8.5 and consequently exact linkage scores can now be computed, rather than approximated.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S189-98 [12169547.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):97-101 [11731797.001]
  • [Cites] Hum Hered. 1971;21(6):523-42 [5149961.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(8):2363-7 [3470801.001]
  • [Cites] Am J Hum Genet. 1993 Jul;53(1):252-63 [8317490.001]
  • [Cites] Am J Hum Genet. 1995 Feb;56(2):519-27 [7847388.001]
  • [Cites] Nat Genet. 1995 Dec;11(4):402-8 [7493020.001]
  • [Cites] Am J Hum Genet. 1996 Jun;58(6):1323-37 [8651310.001]
  • [Cites] Am J Hum Genet. 1996 Jun;58(6):1347-63 [8651312.001]
  • [Cites] J Comput Biol. 1998 Spring;5(1):1-7 [9541867.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1015-6 [16195711.001]
  • [Cites] Am J Hum Genet. 2006 Jun;78(6):922-35 [16685644.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Am J Hum Genet. 2008 Mar;82(3):607-22 [18319071.001]
  • [Cites] Nat Genet. 2000 May;25(1):12-3 [10802644.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):963-77 [11254453.001]
  • [Cites] Am J Hum Genet. 2003 Feb;72(2):375-83 [12509788.001]
  • (PMID = 19477987.001).
  • [ISSN] 1367-4811
  • [Journal-full-title] Bioinformatics (Oxford, England)
  • [ISO-abbreviation] Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2687978
  •  go-up   go-down


14. Silva CM, Lima GA, Machado EO, Van Haute FR, Gadelha MR: Transient central diabetes insipidus followed by pituitary apoplexy treated in a conservative way. Arq Neuropsiquiatr; 2008 Jun;66(2B):415-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transient central diabetes insipidus followed by pituitary apoplexy treated in a conservative way.
  • [MeSH-major] Diabetes Insipidus / etiology. Pituitary Apoplexy / complications. Pituitary Apoplexy / therapy
  • [MeSH-minor] Adenoma / complications. Adenoma / diagnosis. Headache / etiology. Humans. Hydrocortisone / blood. Hypertension / complications. Male. Middle Aged. Pituitary Gland / physiology. Pituitary Neoplasms / complications

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes Insipidus.
  • MedlinePlus Health Information. consumer health - Diabetes Insipidus.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641885.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


15. Shi J, Zhang JM, Wu Q, Chen G, Zhang H, Bo WL: Granulomatous hypophysitis: two case reports and literature review. J Zhejiang Univ Sci B; 2009 Jul;10(7):552-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulomatous hypophysitis (GRH) is extremely rare and commonly presents with chronic inflammatory of the enlarged pituitary gland.
  • In our study, 66-year-old and 57-year-old women, both Chinese, were diagnosed with GRH presenting preoperatively definite imageology characters as pituitary adenoma.
  • Consequently, the patient was diagnosed with probable invasive pituitary adenoma.
  • The other 57-year-old woman complained a light headache and had been previously treated as nonfunctional pituitary adenoma in other hospital.
  • Clinically and radiologically, GRH is a rare sellar entity easily to be misdiagnosed as a pituitary adenoma.
  • Trans-sphenoidal surgery can decompress the optical nerve or oculomotornerve as a therapeutic strategy, and support biopsy or further pathological diagnosis.
  • [MeSH-major] Granuloma / complications. Granuloma / diagnosis. Hypopituitarism / complications. Hypopituitarism / diagnosis

  • Genetic Alliance. consumer health - Granulomatous Hypophysitis.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for granulomatous hypophysitis .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Sci. 1999 Nov;318(5):339-42 [10555098.001]
  • [Cites] J Clin Neurosci. 2007 Mar;14(3):286-8 [17188492.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1399-406 [11070106.001]
  • [Cites] Clin Neuropathol. 2000 Nov-Dec;19(6):300-4 [11128623.001]
  • [Cites] J Neuroophthalmol. 2001 Mar;21(1):34-6 [11315980.001]
  • [Cites] Br J Neurosurg. 2001 Jun;15(3):242-5, discussion 245-6 [11478060.001]
  • [Cites] J Neuroradiol. 2002 Mar;29(1):43-8 [11984478.001]
  • [Cites] Neurocirugia (Astur). 2002 Apr;13(2):137-41 [12058606.001]
  • [Cites] Endocr Pathol. 2002 Fall;13(3):183-95 [12446917.001]
  • [Cites] Intern Med. 2003 Feb;42(2):168-73 [12636236.001]
  • [Cites] J Neurosurg. 1980 Apr;52(4):584-7 [7373382.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1985 Sep;48(9):949-51 [4045491.001]
  • [Cites] Neurosurgery. 1988 Jan;22(1 Pt 1):133-6 [3344071.001]
  • [Cites] Endocrinol Jpn. 1988 Aug;35(4):607-16 [3215147.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):681-6 [2809721.001]
  • [Cites] Med Clin (Barc). 1990 Jun 16;95(3):100-2 [2250515.001]
  • [Cites] Neth J Med. 1991 Oct;39(3-4):136-41 [1791874.001]
  • [Cites] Intern Med. 1992 Sep;31(9):1147-50 [1421728.001]
  • [Cites] Acta Neurochir (Wien). 1993;121(3-4):152-8 [8512013.001]
  • [Cites] Neurosurgery. 1994 Sep;35(3):505-8; discussion 508 [7800142.001]
  • [Cites] Acta Neuropathol. 1995;90(6):637-44 [8615086.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Oct;45(4):499-503 [8959092.001]
  • [Cites] Neuroradiology. 1997 Jan;39(1):7-11 [9121653.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):713-22; discussion 722-3 [9092844.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Oct;37(10):766-70 [9362138.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Mar;19(3):439-44 [9541295.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):146-9 [9657201.001]
  • [Cites] Clin Endocrinol (Oxf). 1998 Jul;49(1):131-4 [9797857.001]
  • [Cites] Endocr Pathol. 2004 Winter;15(4):359-63 [15681861.001]
  • [Cites] Am J Surg Pathol. 2005 Mar;29(3):329-38 [15725801.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):489-94 [15799151.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):599-614 [15634713.001]
  • [Cites] Neurol India. 2005 Sep;53(3):364-5 [16230818.001]
  • [Cites] J Clin Neurosci. 2006 Dec;13(10):1062-6 [17113990.001]
  • [Cites] AJNR Am J Neuroradiol. 2000 Sep;21(8):1466-9 [11003280.001]
  • (PMID = 19585674.001).
  • [ISSN] 1862-1783
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 37
  • [Other-IDs] NLM/ PMC2704974
  •  go-up   go-down


16. Krzentowska A, Gołkowski F, Bałdys-Waligórska A, Hubalewska-Dydejczyk A: [Gastrointestinal tract polyps in acromegaly patients]. Przegl Lek; 2010;67(12):1266-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acromegaly is a rare, chronic disease due to hypersecretion of growth hormone (GH) by pituitary adenoma arising from somatotrophs.
  • Polyps were histopatologically verified as tubular adenoma with low-grade dysplasia (10 patients, 76.9%) and hyperplastic polyps (3 patients, 23.1%).
  • IGF-1, GH basic and in 120 min of OGTT serum concentrations on diagnosis were not significantly related to the prevalence of colon polyps.
  • Our study indicates that duration of uncontrolled acromegaly, contrary to IGF-1, GH basic and in OGTT serum concentrations at diagnosis are essential for the colon polyps development.

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21591351.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


17. Lahera Vargas M, da Costa CV: [Prevalence, etiology and clinical findings of Cushing's syndrome]. Endocrinol Nutr; 2009 Jan;56(1):32-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Prevalencia, etiología y cuadro clínico del síndrome de Cushing.
  • Age at diagnosis of Cushing's syndrome varies according to the etiology.
  • Most cases of Cushing's disease are due to a pituitary adenoma, although the tumor may not be visible on the available imaging techniques.
  • ACTH-independent Cushing's syndrome is found in 20% of cases and is most frequently due to adenomas (10%) or adrenal carcinomas (8).
  • [MeSH-minor] ACTH Syndrome, Ectopic / complications. Adenoma / complications. Adenoma / secretion. Adrenal Cortex / pathology. Adrenal Cortex Neoplasms / complications. Adrenal Cortex Neoplasms / secretion. Carcinoma / complications. Carcinoma / secretion. Cardiovascular Diseases / epidemiology. Diabetes Mellitus / epidemiology. Female. Glucocorticoids / adverse effects. Humans. Hydrocortisone / secretion. Hyperplasia. Incidence. Male. Phenotype. Pituitary ACTH Hypersecretion / complications. Pituitary Neoplasms / complications. Pituitary Neoplasms / secretion. Prevalence. Risk

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Cushing's Syndrome.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627706.001).
  • [ISSN] 1575-0922
  • [Journal-full-title] Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición
  • [ISO-abbreviation] Endocrinol Nutr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Glucocorticoids; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 59
  •  go-up   go-down


18. Pouratian N, Prevedello DM, Jagannathan J, Lopes MB, Vance ML, Laws ER Jr: Outcomes and management of patients with Cushing's disease without pathological confirmation of tumor resection after transsphenoidal surgery. J Clin Endocrinol Metab; 2007 Sep;92(9):3383-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Despite the success of transsphenoidal surgery (TSS) for the treatment of Cushing's disease, in a number of cases, an ACTH-staining pituitary adenoma is not identified histologically.
  • PATIENTS: Of 490 TSS procedures for Cushing's disease between 1993 and 2004, we identified 111 cases without histological adenoma confirmation.
  • RESULTS: Overall, 50% of these patients achieved remission, a figure lower than for our entire series (79%) and for patients with histological confirmation of an ACTH-staining adenoma (88%) (P < 0.001).
  • CONCLUSION: The lower remission rate in patients without histological evidence of an adenoma is most likely a result of a decreased rate of adenoma extirpation.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / surgery. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / surgery
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual. Prognosis. Remission Induction. Retrospective Studies. Treatment Failure. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Endocrinol Metab. 2008 Jan;4(1):14-5 [17940518.001]
  • (PMID = 17595252.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Machiavelli G, Cotignola J, Danilowicz K, Carbonara C, Paes de Lima A, Basso A, Bruno OD, Szijan I: Expression of p16(INK4A) gene in human pituitary tumours. Pituitary; 2008;11(1):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p16(INK4A) gene in human pituitary tumours.
  • Pituitary adenomas comprise 10-15% of primary intracranial tumours but the mechanisms leading to tumour development are yet to be clearly established.
  • We studied the cyclin-dependent kinase inhibitor p16(INK4A) gene expression at mRNA level in human pituitary adenomas.
  • The RT-PCR assay and electrophoresis of the PCR-products showed that p16(INK4A) mRNA was undetectable in: 62% of non-functioning, 8% of growth hormone-secreting, 17% of prolactin-secreting and 17% of adrenocorticotropin-secreting adenomas.
  • Within the non-functioning adenomas 63% were "null cell" and 37% were positive for some hormone, both subgroups showed similar percentage of cases with absence of p16(INK4A) mRNA.
  • Our results show that clinically non-functioning macroadenomas have impaired p16(INK4A) expression in a clearly higher proportion than any other pituitary tumour subtype investigated.
  • [MeSH-major] Adenoma / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Gene Expression Regulation, Neoplastic. Pituitary Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2493-6 [8653683.001]
  • [Cites] Acta Endocrinol (Copenh). 1993 Jul;129 Suppl 1:1-5 [8396832.001]
  • [Cites] Trends Endocrinol Metab. 1998 Jan-Feb;9(1):20-6 [18406230.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Sep;41(3):359-64 [7893282.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Sep;91(9):3316-23 [16787992.001]
  • [Cites] Oncol Rep. 2000 Mar-Apr;7(2):421-5 [10671696.001]
  • [Cites] J Pathol. 2001 Apr;193(4):491-7 [11276008.001]
  • [Cites] Int J Cancer. 1995 Mar 29;61(1):115-20 [7705923.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Sep;77(3):644-6 [7690360.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):44-50 [10389976.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Apr;24(4):328-36 [10092131.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):704-7 [8259215.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Sep;51(3):317-25 [10469011.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):189-99 [17047382.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Mol Endocrinol. 1999 Nov;13(11):1801-10 [10551774.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):398-403 [15892297.001]
  • (PMID = 18058237.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger
  •  go-up   go-down


20. Cónsole GM, Hereñú CB, Camihort GA, Luna GC, Ferese C, Goya RG: Effect of insulin-like growth factor-I gene therapy on the somatotropic axis in experimental prolactinomas. Cells Tissues Organs; 2009;190(1):20-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gene therapy was implemented in young female Sprague-Dawley rats which received 2 pituitary stereotaxic injections of a control recombinant adenoviral vector expressing green fluorescent protein (RAd-GFP) or IGF-I (RAd-IGF-I).
  • The treatment of pituitary adenomas with RAd-IGF-I induced a significant (p < 0.05) decrease in cell size with respect to E(2) + RAd-GFP (51.3 +/- 0.3 vs. 58.9 +/- 0.3 microm(2)) and no changes in cell density compared with RAd-GFP-injected animals (12.8 +/- 1.7 vs. 10.5 +/- 0.1).
  • In rats carrying estrogen-induced adenomas, RAd-IGF-I injection induced a significant (p < 0.05) decrease in serum growth hormone compared to RAd-GFP-injected animals (107.5 +/- 7 vs. 142.4 +/- 9 ng/ml).
  • IGF-I gene therapy appears to be an effective approach for the treatment of experimental somatomammotropic pituitary tumors and could be potentially useful as an adjuvant of conventional therapies.
  • [MeSH-major] Genetic Therapy. Insulin-Like Growth Factor I / genetics. Insulin-Like Growth Factor I / therapeutic use. Pituitary Neoplasms / therapy. Prolactinoma / genetics. Prolactinoma / therapy. Somatotrophs / pathology

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18957836.001).
  • [ISSN] 1422-6421
  • [Journal-full-title] Cells, tissues, organs
  • [ISO-abbreviation] Cells Tissues Organs (Print)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Estrogens; 147336-22-9 / Green Fluorescent Proteins; 67763-96-6 / Insulin-Like Growth Factor I; 9002-62-4 / Prolactin; 9002-72-6 / Growth Hormone
  •  go-up   go-down


21. El-Banhawy OA, Halaka AN, Ayad H, El-Altuwaijri M, El-Sharnoby MM: Long-term endonasal endoscopic review of successful duraplasty after endonasal endoscopic skull base surgery. Am J Rhinol; 2008 Mar-Apr;22(2):175-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty patients had pituitary adenomas, 25 with macroadenomas and 15 with microadenomas.

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18416976.001).
  • [ISSN] 1050-6586
  • [Journal-full-title] American journal of rhinology
  • [ISO-abbreviation] Am J Rhinol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Yamada S, Ohyama K, Taguchi M, Takeshita A, Morita K, Takano K, Sano T: A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas. Neurosurgery; 2007 Sep;61(3):580-4; discussion 584-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of the correlation between morphological findings and biological activities in clinically nonfunctioning pituitary adenomas.
  • OBJECTIVE: The aims of this study are to review the histology of the clinically nonfunctioning pituitary adenomas (CNFPAs) we have observed and to determine whether or not the frequency of cavernous sinus invasion is different among each type of morphology.
  • METHODS: In addition, several proliferative markers, including Ki67, p53, E-cadherin, matrix metallo-proteinase 9 and pituitary tumor derived fibroblast growth factor receptor 4 (ptd-FGFR4), were also investigated in invasive and non-invasive tumors.
  • RESULTS: Our consequent 213 CNFPAs were diagnosed as follows: 64% were silent gonadotroph adenomas, 18% were null cell adenomas, 12% were silent corticotroph adenomas, 4% were silent Subtype 3 adenomas, and 1% were other types of adenomas.
  • Female patients or younger patients showed a significant preponderance in silent corticotroph adenomas and in silent Subtype 3 adenomas, respectively.
  • Cavernous sinus invasion occurs most frequently in silent corticotroph adenomas (85%) followed by Subtype 3 adenomas (67%), null cell adenomas (38%), and silent gonadotroph adenomas (11%).
  • Therefore, we suggest that all CNFPAs be examined not only by conventional light microscopy but also by immunohistochemistry, preferably by electron microscopy, to achieve a correct morphological diagnosis.
  • [MeSH-major] Adenoma / classification. Adenoma / pathology. Pituitary Neoplasms / classification. Pituitary Neoplasms / pathology


23. Saeger W: Pituitary tumors: prognostic indicators. Endocrine; 2005 Oct;28(1):57-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary tumors: prognostic indicators.
  • Many factors influence the proliferation of pituitary adenomas: angiogenesis, apoptosis, growth factors, oncogenes, tumor suppressor genes, and hormone receptors.
  • Pituitary adenomas can be enclosed or invasive and may be very large or may be microadenomas, but the most important point for prognosis is the total resection in the first or second surgery or the reaction on treatments by drugs.
  • [MeSH-major] Adenoma / pathology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1993 Nov;33(5):907-9; discussion 909-10 [8264892.001]
  • [Cites] Pituitary. 2002;5(2):55-65 [12675502.001]
  • [Cites] Front Neuroendocrinol. 2000 Jul;21(3):174-98 [10882539.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):210-6 [15670198.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1205-12 [12429800.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2493-6 [8653683.001]
  • [Cites] Endocr Pathol. 2001 Summer;12(2):171-80 [11579683.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Jan;66(1):16-23 [2891720.001]
  • [Cites] Dtsch Med Wochenschr. 1999 Oct 1;124(39):1148-52 [10544687.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 May;46(5):599-606 [9231056.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):352-60 [11838811.001]
  • [Cites] Mol Carcinog. 1997 Aug;19(4):221-4 [9290697.001]
  • [Cites] Neurol Res. 1985 Sep;7(3):153-60 [2866460.001]
  • [Cites] Pathol Res Pract. 1991 Jun;187(5):632-6 [1923959.001]
  • [Cites] Endocr Rev. 1992 May;13(2):220-40 [1352243.001]
  • [Cites] J Histochem Cytochem. 2001 Sep;49(9):1193-4 [11511691.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):767-74 [10079254.001]
  • [Cites] J Neurosurg. 1987 Dec;67(6):803-6 [3681419.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):809-14 [7889618.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):429-32 [12507069.001]
  • [Cites] J Neurosurg. 1998 Jun;88(6):1002-8 [9609294.001]
  • [Cites] Am J Pathol. 1997 Feb;150(2):401-7 [9033255.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6794-9 [11156367.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8 [12107192.001]
  • [Cites] Gen Diagn Pathol. 1995 Oct;141(2):81-92 [8548598.001]
  • [Cites] Front Neuroendocrinol. 1998 Apr;19(2):128-50 [9578983.001]
  • [Cites] J Child Neurol. 2001 May;16(5):364-7 [11392522.001]
  • [Cites] Eur J Endocrinol. 1995 Dec;133(6):686-90 [8548053.001]
  • [Cites] Endocr Pathol. 2001 Spring;12(1):39-47 [11478267.001]
  • [Cites] Pituitary. 1999 May;1(3-4):213-20 [11081200.001]
  • [Cites] Endocr Relat Cancer. 2000 Mar;7(1):3-15 [10808192.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1136-40 [15734994.001]
  • [Cites] Histol Histopathol. 1987 Apr;2(2):135-42 [2980713.001]
  • [Cites] Braz J Med Biol Res. 2004 Feb;37(2):235-43 [14762579.001]
  • [Cites] Endocr Pathol. 1998 Spring;9(1):53-62 [12114662.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3084-9 [12107205.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Nov;79(5):1513-6 [7962351.001]
  • [Cites] Cancer Res. 1997 Dec 15;57(24):5446-51 [9407947.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jan;26(1):65-7 [15661703.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Sep;53(3):337-44 [10971451.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jan;78(1):89-93 [8288721.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7):1562-6 [10197629.001]
  • [Cites] Acta Neuropathol. 1977 Aug 16;39(2):165-7 [899741.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1262-7 [11889197.001]
  • [Cites] Eur J Endocrinol. 1999 Mar;140(3):250-5 [10216521.001]
  • [Cites] Eur J Endocrinol. 1997 Apr;136(4):382-7 [9150697.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1613-6 [7712461.001]
  • [Cites] Clin Neuropathol. 2005 Mar-Apr;24(2):56-63 [15803804.001]
  • [Cites] Endocr Pathol. 2000 Winter;11(4):295-300 [12114754.001]
  • [Cites] Eur J Endocrinol. 2001 Aug;145(2):137-45 [11454508.001]
  • [Cites] Braz J Med Biol Res. 2002 May;35(5):561-5 [12011941.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Apr;24(4):328-36 [10092131.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):328-41 [11414475.001]
  • [Cites] Virchows Arch. 2001 Apr;438(4):321-35 [11355165.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2635-43 [12050228.001]
  • [Cites] J Neurosurg. 1993 May;78(5):753-61 [8096873.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1088-96 [15234043.001]
  • [Cites] Can J Neurol Sci. 2003 Aug;30(3):215-9 [12945944.001]
  • [Cites] Brain Pathol. 2002 Oct;12 (4):412-9 [12408227.001]
  • [Cites] Radiology. 1990 Oct;177(1):273-5 [2399329.001]
  • [Cites] J Endocrinol. 2000 May;165(2):475-81 [10810311.001]
  • [Cites] Endocrinology. 2002 Oct;143(10):3759-65 [12239085.001]
  • [Cites] Endocr Pathol. 1996 Spring;7(1):63-70 [12114681.001]
  • [Cites] Zentralbl Neurochir. 1979;40(2):131-6 [539216.001]
  • [Cites] Microsc Res Tech. 1992 Jan 15;20(2):162-76 [1547357.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Feb;81(2):656-62 [8636285.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Apr;56(4):541-51 [11966748.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3210-2 [9745428.001]
  • [Cites] J Neurosurg. 2002 Feb;96(2):195-208 [11838791.001]
  • [Cites] Eur J Endocrinol. 2000 Jul;143(1):R1-6 [10870044.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1604-10 [9589663.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):313-23 [10027389.001]
  • [Cites] Neurol Res. 1998 Dec;20(8):709-12 [9864735.001]
  • (PMID = 16311411.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 90
  •  go-up   go-down


24. Lania AG, Ferrero S, Pivonello R, Mantovani G, Peverelli E, Di Sarno A, Beck-Peccoz P, Spada A, Colao A: Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J Clin Endocrinol Metab; 2010 Jan;95(1):13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation.
  • CONTEXT: Mixed PRL- and GH-secreting pituitary adenomas are relatively common because somatotrophs and lactotrophs share the common somato-mammotroph progenitor lineage.
  • [MeSH-major] GTP-Binding Protein alpha Subunits, Gs / genetics. Growth Hormone-Secreting Pituitary Adenoma / genetics. Growth Hormone-Secreting Pituitary Adenoma / pathology. Pituitary Neoplasms / pathology. Prolactinoma / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19890024.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.1.- / GNAS protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


25. Radaelli E, Arnold A, Papanikolaou A, Garcia-Fernandez RA, Mattiello S, Scanziani E, Cardiff RD: Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas. Vet Pathol; 2009 Jul;46(4):736-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammary tumor phenotypes in wild-type aging female FVB/N mice with pituitary prolactinomas.
  • Prolactin-secreting pituitary adenomas are common spontaneous lesions in aging FVB females.
  • Prolactin-secreting pituitary proliferations play a significant role in mouse mammary tumorigenesis generally producing adenosquamous carcinomas.
  • Since genetically engineered FVB mice are frequently used to study mammary tumor biology, we have examined a cohort of 64 aging wild-type FVB/N females to establish the prevalence and the nature of spontaneous mammary and pituitary tumors.
  • Tissues from mammary and pituitary glands were studied by histopathology and immunohistochemistry.
  • Of the 64 examined mice, 20 had pituitary tumors and 20 had mammary tumors.
  • Mammary and pituitary tumors were associated in 17 mice.
  • All pituitary tumors were prolactin-positive by immunohistochemistry and classified as prolactinomas.
  • Compared with previous reports, prolactinoma-associated mammary tumors displayed a broader morphologic spectrum, including cases with the EMT phenotype.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19276050.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA141582; United States / NCI NIH HHS / CA / CA55909
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Swords FM, Monson JP, Besser GM, Chew SL, Drake WM, Grossman AB, Plowman PN: Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy. Eur J Endocrinol; 2009 Dec;161(6):819-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery: a safe and effective salvage treatment for pituitary tumours not controlled despite conventional radiotherapy.
  • OBJECTIVE: We report the use of 'gamma knife' (GK) radiosurgery in 25 patients with pituitary adenomas not cured despite conventional therapy, including external beam radiotherapy.
  • PATIENTS AND METHODS: All patients had previously received conventional radiotherapy for a mean of 11.8 years prior to receiving GK; 23 out of 25 had also undergone pituitary surgery on at least one occasion.
  • Seventeen had hyperfunctioning adenomas that still required medical therapy without an adequate biochemical control--ten somatotroph adenomas, six corticotroph adenomas and one prolactinoma, while eight patients had non-functioning pituitary adenomas (NFPAs).
  • The results in corticotroph adenomas were variable.
  • Prior to GK, 72% of the patients were panhypopituitary, and 42% of the remainder have developed new anterior pituitary hormone deficiencies to date.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19773368.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


27. Widhalm G, Wolfsberger S, Preusser M, Fischer I, Woehrer A, Wunderer J, Hainfellner JA, Knosp E: Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression. J Neurosurg; 2009 Sep;111(3):563-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual nonfunctioning pituitary adenomas: prognostic value of MIB-1 labeling index for tumor progression.
  • OBJECT: In residual nonfunctioning pituitary adenomas, reliable prognostic parameters indicating probability of tumor progression are needed.
  • METHODS: The authors studied a cohort of 92 patients with nonfunctioning pituitary adenomas.
  • Additionally, the time period to second surgery was significantly shorter in residual adenomas showing an MIB-1 LI>3%.
  • CONCLUSIONS: The data indicate that MIB-1 LI in nonfunctioning pituitary adenomas is a clinically useful prognostic parameter indicating probability of progression of postoperative tumor remnants.
  • [MeSH-major] Adenoma / diagnosis. Ki-67 Antigen / analysis. Pituitary Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm, Residual / diagnosis. Postoperative Period. Prognosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991501.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


28. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M: Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery; 2007 Jun;60(6):993-1002; discussion 1003-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients.
  • OBJECTIVE: Giant pituitary adenomas, defined as those measuring at least 4 cm in maximum diameter, are a therapeutic challenge.
  • We report our experience in a large, consecutive series of patients with giant adenomas.
  • METHODS: Between 1990 and 2004, 95 patients with a giant pituitary adenomas underwent surgery at our department.
  • Nonfunctioning pituitary adenoma was the most frequent type (n = 70; 73.7%), whereas hormone-secreting adenomas numbered only 25 (26.3%).
  • This was not different in patients with nonfunctioning pituitary adenomas compared with patients with hormone-secreting tumors.
  • In the subgroup of patients with nonfunctioning pituitary adenomas, radiation therapy had a protective role against tumor growth (P < 0.01).
  • CONCLUSION: Maximal surgical removal of giant adenomas through the transsphenoidal or transcranial approach, or both, aimed to relieve compression of the optic pathway and reduce tumor volume as much as possible, offers the best chances to control the tumor when followed with adjuvant medical and radiation therapies.
  • [MeSH-major] Adenoma / pathology. Adenoma / therapy. Neurosurgical Procedures / methods. Pituitary Neoplasms / pathology. Pituitary Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538372.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Biermasz NR, Dekkers OM, Voormolen J, de Keizer RJ, Neelis KJ, Wiggers-de Bruïne FT, Smit JW, Arias AM, Romijn JA: [Transsphenoidal resection of pituitary adenomas: long-term results from the Leiden University Medical Center]. Ned Tijdschr Geneeskd; 2008 Nov 22;152(47):2565-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transsphenoidal resection of pituitary adenomas: long-term results from the Leiden University Medical Center].
  • OBJECTIVE: To evaluate the long-term outcome of transsphenoidal resection of pituitary adenomas at the Leiden University Medical Center (LUMC), The Netherlands.
  • METHOD: 416 consecutive patients undergoing surgery for pituitary adenoma at the LUMC between 1978 and 2004 were included; 174 patients with non-functioning macroadenomas (NFMA), 164 patients with acromegaly and 78 patients with Cushing's disease.
  • RESULTS: Biochemical remission was achieved in 66% of patients with acromegaly, and 72% of patients with Cushing's disease; incidence of pituitary failure was low in these patients (5% and 18% respectively).
  • In 82% of the patients with NFMA visual function improved whereas the percentage with any degree of pituitary failure increased from 85% (preoperatively) to 95% (postoperatively).
  • CONCLUSION: Transsphenoidal resection is an effective treatment in most, but not all, patients with pituitary adenomas.
  • The surgical results at the LUMC are comparable with those obtained in important international centres.
  • [MeSH-major] Adenoma / surgery. Hypophysectomy / methods. Pituitary Neoplasms / surgery
  • [MeSH-minor] Acromegaly / pathology. Acromegaly / surgery. Adult. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pituitary ACTH Hypersecretion / pathology. Pituitary ACTH Hypersecretion / surgery. Remission Induction. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ned Tijdschr Geneeskd. 2008 Nov 22;152(47):2537-43 [19174932.001]
  • (PMID = 19174939.001).
  • [ISSN] 0028-2162
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


30. Chesnokova V, Melmed S: Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):55-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary senescence: the evolving role of Pttg.
  • Despite the high prevalence of pituitary adenomas they are invariably benign, indicative of unique intrinsic mechanisms controlling pituitary cell proliferation.
  • Here we discuss prospective mechanisms underlying senescence-associated molecular pathways activated in benign pituitary adenomas.
  • Both deletion and over-expression of pituitary tumor transforming gene (Pttg) promote chromosomal instability and aneuploidy.
  • Abundant PTTG in GH-secreting pituitary adenomas also triggers p21-dependent senescence.
  • Pituitary p21 may therefore safeguard against further chromosomal instability by constraining pituitary tumor growth.
  • These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1729-33 [11748253.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):503-11 [11850775.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] Cell. 2003 Jun 13;113(6):703-16 [12809602.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Exp Cell Res. 1961 Dec;25:585-621 [13905658.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):6-10 [15692944.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] Trends Genet. 2008 Feb;24(2):77-85 [18192065.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell. 2008 Jun 13;133(6):958-61 [18555773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):81-94 [19132009.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):677-8 [19223763.001]
  • [Cites] Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82 [19650784.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Cell. 2007 Jul 27;130(2):223-33 [17662938.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • (PMID = 20153804.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-11A1; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / R01 CA075979-11A1
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Other-IDs] NLM/ NIHMS185500; NLM/ PMC2906651
  •  go-up   go-down


31. Yaldizli O, Muroi C, Keller E: An unusual complication of a successful cardiopulmonary reanimation. Am J Emerg Med; 2008 Jun;26(5):639.e1-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of a 50-year-old man who experienced acute cardiac arrest after transsphenoidal resection of a pituitary adenoma.
  • [MeSH-minor] Adenoma / surgery. Humans. Male. Middle Aged. Pituitary Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Cardiac Arrest.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18534321.001).
  • [ISSN] 1532-8171
  • [Journal-full-title] The American journal of emergency medicine
  • [ISO-abbreviation] Am J Emerg Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Collie RB, Collie MJ: Extracranial thyroid-stimulating hormone-secreting ectopic pituitary adenoma of the nasopharynx. Otolaryngol Head Neck Surg; 2005 Sep;133(3):453-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extracranial thyroid-stimulating hormone-secreting ectopic pituitary adenoma of the nasopharynx.
  • [MeSH-major] ACTH Syndrome, Ectopic / diagnosis. Adenoma / diagnosis. Adenoma / secretion. Choristoma / diagnosis. Nasopharyngeal Neoplasms / diagnosis. Nasopharyngeal Neoplasms / secretion. Pituitary Gland. Thyrotropin / secretion

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16143200.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-71-5 / Thyrotropin
  •  go-up   go-down


33. Candrina R, Sleiman I, Zorzi F: ACTH-secreting pituitary adenoma within an ovarian teratoma. Eur J Intern Med; 2005 Sep;16(5):359-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACTH-secreting pituitary adenoma within an ovarian teratoma.
  • The differential diagnosis of Cushing's syndrome is one of the most difficult tasks in medicine, and it is especially problematic in cases with "occult" ectopic ACTH syndrome.
  • We describe the case of a 26-year-old woman who was found to suffer from ectopic ACTH syndrome due to pituitary microadenoma, localized within a mature ovarian teratoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16137552.001).
  • [ISSN] 0953-6205
  • [Journal-full-title] European journal of internal medicine
  • [ISO-abbreviation] Eur. J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


34. Bladowska J, Sokolska V, Sozański T, Bednarek-Tupikowska G, Sąsiadek M: Comparison of post-surgical MRI presentation of the pituitary gland and its hormonal function. Pol J Radiol; 2010 Jan;75(1):29-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of post-surgical MRI presentation of the pituitary gland and its hormonal function.
  • BACKGROUND: Post-surgical evaluation of the pituitary gland in MRI is difficult because of a change of anatomical conditions.
  • It depends also on numerous other factors, including: size and expansion of a tumour before surgery, type of surgical access, quality and volume of filling material used and time of its resorption.The aim of the study was to compare MR image of the pituitary gland after surgery with clinical findings and to establish a correlation between MRI presentation of spared pituitary and its hormonal function.
  • MATERIAL/METHODS: 124 patients after resection of pituitary adenomas - 409 MRI results in total - were studied.
  • RESULTS: The pituitary gland seemed to be normal in MRI in 11 patients, 8 of them had completely regular pituitary function but in 3 of them we noticed a partial hypopituitarism.
  • In 99 patients only a part of the pituitary gland was recognised, 53 of them had hypopituitarism but 46 of them were endocrinologically healthy.
  • 14 patients seemed to have no persistent pituitary gland in MRI, in comparison to hormonal studies: there was panhypopituitarism in 6 and hypopituitarism in 8 cases.
  • CONCLUSIONS: MRI presentation of post - surgical pituitary gland doesn't necessarily correlate with its hormonal function - there was a significant statistical difference.
  • Some patients with partial pituitary seems normal hormonal function.
  • In some cases the pituitary seem normal in MRI but these patients have hormonal disorders and need substitution therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Przegl Lek. 1999;56(10):638-43 [10695377.001]
  • [Cites] Mayo Clin Proc. 1999 Jul;74(7):661-70 [10405694.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jun-Jul;22(6):1097-104 [11415904.001]
  • [Cites] Neurol Neurochir Pol. 2002 Nov-Dec;36(6):1121-30; discussion 1131-3 [12715689.001]
  • [Cites] Clin Neurol Neurosurg. 2007 Feb;109(2):111-24 [17126479.001]
  • [Cites] Neuro Endocrinol Lett. 2007 Oct;28(5):560-4 [17984954.001]
  • [Cites] Neuroradiology. 2008 Mar;50(3):213-20 [18034233.001]
  • [Cites] J Neurosurg. 2008 Apr;108(4):715-28 [18377251.001]
  • [Cites] Curr Opin Endocrinol Diabetes Obes. 2008 Aug;15(4):371-5 [18594279.001]
  • [Cites] Endokrynol Pol. 2008 Jul-Aug;59(4):348-51 [18777506.001]
  • [Cites] J Neurooncol. 2009 Jan;91(2):191-8 [18825316.001]
  • [Cites] Neuroradiology. 1996 Nov;38(8):747-54 [8957799.001]
  • [Cites] Acta Radiol. 1997 Jan;38(1):30-6 [9059398.001]
  • [Cites] Acta Radiol. 1992 Sep;33(5):396-9 [1389642.001]
  • [Cites] Radiology. 1992 Nov;185(2):521-7 [1410366.001]
  • [Cites] Clin Radiol. 1994 Aug;49(8):524-30 [7955862.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:16-7 [8738486.001]
  • [Cites] Surg Neurol. 1997 Mar;47(3):213-22; discussion 222-3 [9068690.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Aug;82(8):2381-5 [9253304.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] J Radiol. 2000 Sep;81(9):939-42 [10992090.001]
  • (PMID = 22802758.001).
  • [ISSN] 1733-134X
  • [Journal-full-title] Polish journal of radiology
  • [ISO-abbreviation] Pol J Radiol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3389853
  • [Keywords] NOTNLM ; MRI / hormonal function / pituitary tumours / surgery
  •  go-up   go-down


35. Quentien MH, Barlier A, Franc JL, Pellegrini I, Brue T, Enjalbert A: Pituitary transcription factors: from congenital deficiencies to gene therapy. J Neuroendocrinol; 2006 Sep;18(9):633-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary transcription factors: from congenital deficiencies to gene therapy.
  • Despite the existence of interspecies phenotypic variability, animal models have yielded valuable insights into human pituitary diseases.
  • Studies on Snell and Jackson mice known to have growth hormone, prolactin and thyroid-stimulating hormone deficiencies involving the hypoplastic pituitary gland have led to identifying alterations of the pituitary specific POU homeodomain Pit-1 transcription factor gene.
  • This finding supports the idea that Tpit plays an essential role in the differentiation of the pro-opiomelanocortin pituitary lineage.
  • Lentiviral vectors expressing a Pit-1 dominant negative mutant induced time- and dose-dependent cell death in somatotroph and lactotroph adenomas in vitro.
  • Gene transfer by lentiviral vectors should provide a promising step towards developing an efficient specific therapeutic approach by which a gene therapy programme for treating human pituitary adenomas could be based.
  • [MeSH-major] Gene Expression Regulation / physiology. Genetic Therapy. Pituitary Diseases / genetics. Pituitary Gland, Anterior / metabolism. Pituitary Hormones / metabolism. Transcription Factor Pit-1 / metabolism
  • [MeSH-minor] Animals. Gene Transfer Techniques. Growth Hormone / metabolism. Homeodomain Proteins / genetics. Homeodomain Proteins / metabolism. Humans. Mice, Neurologic Mutants. Mutation / genetics. Pituitary Neoplasms / genetics. Pituitary Neoplasms / physiopathology. Pituitary Neoplasms / therapy. Prolactin / metabolism. T-Box Domain Proteins. Thyrotropin / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879162.001).
  • [ISSN] 0953-8194
  • [Journal-full-title] Journal of neuroendocrinology
  • [ISO-abbreviation] J. Neuroendocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Pituitary Hormones; 0 / T-Box Domain Proteins; 0 / TBX19 protein, human; 0 / Transcription Factor Pit-1; 0 / Transcription Factors; 184787-43-7 / homeobox protein PITX2; 9002-62-4 / Prolactin; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone
  • [Number-of-references] 98
  •  go-up   go-down


36. Sharma SG, Gokden M, McKenney JK, Phan DC, Cox RM, Kelly T, Gokden N: The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features. Appl Immunohistochem Mol Morphol; 2010 Dec;18(6):494-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of the NRCPN, 9/66 (14%) is positive for PAX-2 [4/10 (40%) ovarian papillary serous carcinomas, 5/9 (56%) uterine papillary serous carcinomas]; RCCma was positive in 28/66 (42%), including 9/9 (100%) papillary thyroid carcinomas, 8/10 (80%) ovarian papillary serous carcinomas, 4/9 (44%) uterine papillary serous carcinomas, 1/10 (10%) papillary urothelial carcinomas, 1/2 (50%) intraductal papillary mucinous carcinomas of the pancreas, 3/3 (100%) choroid plexus papillomas, 1/1 (100%) pituitary adenoma with papillary features, and 1/2 (50%) lung adenocarcinomas with papillary features.
  • [MeSH-major] Advanced Glycosylation End Product-Specific Receptor / analysis. Biomarkers, Tumor / analysis. Carcinoma, Papillary / chemistry. Carcinoma, Papillary / diagnosis. Carcinoma, Renal Cell / chemistry. Carcinoma, Renal Cell / diagnosis. Immunohistochemistry. Kidney Neoplasms / chemistry. Kidney Neoplasms / diagnosis. PAX2 Transcription Factor
  • [MeSH-minor] Biopsy. Cell Nucleus / chemistry. Diagnosis, Differential. Female. Humans. Kidney / pathology. Neoplasm Metastasis. Predictive Value of Tests. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Papillary renal cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21102195.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Advanced Glycosylation End Product-Specific Receptor; 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor
  •  go-up   go-down


37. Tajima T, Tsubaki J, Ishizu K, Jo W, Ishi N, Fujieda K: Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. Endocr J; 2008 Jul;55(3):595-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
  • We described a clinical course of a 15-year-old boy of McCune-Albright syndrome (MAS) with pituitary gigantism.
  • At the age of 8 years, a growth hormone (GH) and prolactin (PRL) producing pituitary adenoma was diagnosed at our hospital.
  • This case demonstrated the difficulty of treating pituitary gigantism due to MAS.

  • Genetic Alliance. consumer health - Gigantism.
  • Genetic Alliance. consumer health - McCune Albright syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18445999.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Delayed-Action Preparations; 0 / Ergolines; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide
  •  go-up   go-down


38. Saveanu A, Jaquet P, Brue T, Barlier A: Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol Cell Endocrinol; 2008 May 14;286(1-2):206-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
  • Dopamine and somatostatin are both involved in the negative control of normal pituitary cells.
  • Dopamine subtype 2 receptor (D2DR) and somatostatin receptor (sst) agonists, mainly directed to sst2, are used in the treatment of pituitary adenomas.
  • Nevertheless, a majority of corticotroph and gonadotroph adenomas and a third of somatotroph adenomas are still not sufficiently controlled by these treatments.
  • D2DR and sst1, 2, 3 and 5 are present in most pituitary adenomas.
  • Moreover, new chimeric compounds with sst2, D2DR and sst5 affinity have shown an increased control of secretion and/or proliferation of different types of pituitary adenomas in cell culture.
  • Together with the multi-sst ligand drugs recently developed, these dopamine-somatostatin ligands represent a new opportunity in the combinatory treatment of pituitary adenomas.
  • [MeSH-major] Adenoma / drug therapy. Pituitary Neoplasms / drug therapy. Receptors, Dopamine D2 / metabolism. Receptors, Somatostatin / metabolism. Somatostatin / metabolism
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Cell Proliferation / drug effects. Dopamine / analogs & derivatives. Dopamine / therapeutic use. Ergolines / therapeutic use. Growth Hormone-Secreting Pituitary Adenoma / drug therapy. Growth Hormone-Secreting Pituitary Adenoma / metabolism. Human Growth Hormone / metabolism. Humans. Octreotide / therapeutic use. Protein Multimerization. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18241980.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Ergolines; 0 / Receptors, Dopamine D2; 0 / Receptors, Somatostatin; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; LL60K9J05T / cabergoline; RWM8CCW8GP / Octreotide; VTD58H1Z2X / Dopamine
  • [Number-of-references] 90
  •  go-up   go-down


39. Jevdjovic T, Bernays RL, Eppler E: Insulin-like growth factor-I mRNA and peptide in the human anterior pituitary. J Neuroendocrinol; 2007 May;19(5):335-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor-I mRNA and peptide in the human anterior pituitary.
  • The pituitary is the central organ regulating virtually all endocrine processes, and pathologies of the pituitary cause manifold adverse effects.
  • Because insulin-like growth factor (IGF)-I appears to be involved in tumour pathogenesis, progression, and persistence, and only few data exist on the cellular synthesis sites of IGF-I, the present study aims to create a basis for further research on pituitary adenomas by investigating the presence of IGF-I in the human pituitary using reverse transcriptase-polymerase chain reaction, in situ hybridisation, immunohistochemistry and immunocytochemistry.
  • IGF-I was expressed in the pituitary, and gene sequence analysis revealed a sequence identical to that found in human liver.
  • In all pituitary samples investigated, IGF-I-immunoreactivity occurred in almost all adrenocorticotrophic hormone (ACTH)-immunoreactive cells.
  • [MeSH-major] Adrenocorticotropic Hormone / metabolism. Growth Hormone / metabolism. Insulin-Like Growth Factor I / metabolism. Pituitary Gland, Anterior / metabolism. RNA, Messenger / metabolism

  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425608.001).
  • [ISSN] 0953-8194
  • [Journal-full-title] Journal of neuroendocrinology
  • [ISO-abbreviation] J. Neuroendocrinol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; 67763-96-6 / Insulin-Like Growth Factor I; 9002-60-2 / Adrenocorticotropic Hormone; 9002-72-6 / Growth Hormone
  •  go-up   go-down


40. Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, Wesseling P, Grotenhuis JA, Hoogerbrugge PM, de Vries IJ, Adema GJ: Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol; 2009 Aug;11(4):394-402
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No Treg accumulation was observed in benign tumors such as meningiomas (n = 10) and pituitary adenomas (n = 5).
  • In conclusion, using ultrasonic tumor aspirates as a biosource we identified Tregs and the PD-L1/PD-1 pathway as immune suppressive mechanisms in malignant but not benign human brain tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Immunol. 2007 Jan;28(1):12-8 [17129764.001]
  • [Cites] Trends Immunol. 2006 Aug;27(8):387-93 [16814607.001]
  • [Cites] Cancer Immunol Immunother. 2007 Mar;56(3):271-85 [16819631.001]
  • [Cites] Nat Med. 2007 Jan;13(1):84-8 [17159987.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):371-80 [17210720.001]
  • [Cites] Nature. 2007 Feb 15;445(7129):771-5 [17220874.001]
  • [Cites] Trends Mol Med. 2007 Mar;13(3):108-16 [17257897.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):18-29 [17185041.001]
  • [Cites] Immunol Rev. 2006 Aug;212:131-48 [16903911.001]
  • [Cites] Springer Semin Immunopathol. 2006 Aug;28(1):17-23 [16838179.001]
  • [Cites] J Neurosurg. 2006 Sep;105(3):430-7 [16961139.001]
  • [Cites] J Immunol. 2006 Nov 15;177(10):6983-90 [17082613.001]
  • [Cites] Trends Immunol. 2006 Dec;27(12):541-4 [17045841.001]
  • [Cites] Neurosurgery. 2006 Nov;59(5):988-99; discussioin 999-1000 [17143233.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):95-105 [17315190.001]
  • [Cites] Cancer Immun. 2007;7:12 [17691714.001]
  • [Cites] Cancer Immunol Immunother. 2007 Nov;56(11):1687-700 [17571260.001]
  • [Cites] J Exp Med. 2007 Sep 3;204(9):2023-30 [17682068.001]
  • [Cites] J Immunol. 2007 Oct 1;179(7):4919-28 [17878392.001]
  • [Cites] Cancer Immunol Immunother. 2008 Jan;57(1):123-31 [17522861.001]
  • [Cites] J Immunol. 2007 Dec 1;179(11):7424-30 [18025186.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1794-802 [18076066.001]
  • [Cites] J Transl Med. 2007;5:67 [18093335.001]
  • [Cites] Histopathology. 2002 Jan;40(1):2-11 [11903593.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):249-58 [12874258.001]
  • [Cites] Nat Rev Immunol. 2003 Jul;3(7):569-81 [12876559.001]
  • [Cites] J Neurooncol. 2003 Aug-Sep;64(1-2):3-11 [12952281.001]
  • [Cites] Cancer Treat Res. 2004;117:249-62 [15015564.001]
  • [Cites] Annu Rev Immunol. 2004;22:531-62 [15032588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4572-7 [15070759.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):29-39 [15072445.001]
  • [Cites] Clin Neuropathol. 2004 Mar-Apr;23(2):47-52 [15074577.001]
  • [Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]
  • [Cites] Neurosurg Rev. 1984;7(2-3):173-7 [6493516.001]
  • [Cites] Ann Surg Oncol. 1994 Mar;1(2):169-78 [7834443.001]
  • [Cites] J Immunol. 1999 Apr 15;162(8):4882-92 [10202033.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] J Natl Cancer Inst. 1999 Aug 18;91(16):1382-90 [10451443.001]
  • [Cites] Neurosurgery. 1999 Oct;45(4):893-5 [10515485.001]
  • [Cites] Cancer Immunol Immunother. 2005 Apr;54(4):307-14 [15599732.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):328-41 [15716863.001]
  • [Cites] J Exp Med. 2005 Apr 4;201(7):1061-7 [15809351.001]
  • [Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]
  • [Cites] J Clin Invest. 2006 Feb;116(2):485-94 [16424940.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3294-302 [16540683.001]
  • [Cites] Neuro Oncol. 2006 Jul;8(3):234-43 [16723631.001]
  • [Cites] J Exp Med. 2006 Jul 10;203(7):1701-11 [16818678.001]
  • [Cites] Eur J Immunol. 2007 Jan;37(1):129-38 [17154262.001]
  • (PMID = 19028999.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Apoptosis Regulatory Proteins; 0 / CD274 protein, human; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  • [Other-IDs] NLM/ PMC2743219
  •  go-up   go-down


41. Vazquez-Martinez R, Martinez-Fuentes AJ, Pulido MR, Jimenez-Reina L, Quintero A, Leal-Cerro A, Soto A, Webb SM, Sucunza N, Bartumeus F, Benito-Lopez P, Galvez-Moreno MA, Castaño JP, Malagon MM: Rab18 is reduced in pituitary tumors causing acromegaly and its overexpression reverts growth hormone hypersecretion. J Clin Endocrinol Metab; 2008 Jun;93(6):2269-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rab18 is reduced in pituitary tumors causing acromegaly and its overexpression reverts growth hormone hypersecretion.
  • Alterations of these GTPases and their associated proteins are emerging as the underlying cause for several human diseases involving dysregulated secretory activities.
  • OBJECTIVE: Herein we investigated the role of Rab18, which negatively regulates hormone secretion by interacting with secretory granules, in relation to the altered functioning of tumoral pituitary somatotropes causing acromegaly.
  • PATIENTS: A total of 18 patients diagnosed with pituitary tumors causing acromegaly (nine patients) or nonfunctioning adenomas (nine patients) underwent endoscopic transsphenoidal surgery.
  • Adenomas were subsequently processed to evaluate Rab18 production in relation to GH secretion.
  • RESULTS: We found that somatotropinoma cells are characterized by a high secretory activity concomitantly with a remarkably reduced Rab18 expression (15%) and protein content levels (30%), as compared with cells from nonfunctioning pituitary adenomas derived from patients with normal or reduced GH plasma levels (100%).
  • Furthermore, immunoelectron microscopy revealed that Rab18 association with the surface of GH-containing secretory granules was significantly lower in somatotropes from acromegalies than nonfunctioning pituitary adenomas.
  • [MeSH-major] Acromegaly / genetics. Adenoma / genetics. Growth Hormone-Secreting Pituitary Adenoma / genetics. Human Growth Hormone / secretion. rab GTP-Binding Proteins / genetics

  • Genetic Alliance. consumer health - Acromegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18349058.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RAB18 protein, human; 0 / RNA, Messenger; 12629-01-5 / Human Growth Hormone; EC 3.6.1.- / rab GTP-Binding Proteins
  •  go-up   go-down


42. Kars M, van der Klaauw AA, Onstein CS, Pereira AM, Romijn JA: Quality of life is decreased in female patients treated for microprolactinoma. Eur J Endocrinol; 2007 Aug;157(2):133-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated this topic in female patients with microprolactinoma, because other pituitary adenomas are associated with decreased quality of life.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Endocrinol. 2007 Dec;157(6):789 [18057388.001]
  • (PMID = 17656590.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Agonists
  •  go-up   go-down


43. Paez-Pereda M, Giacomini D, Echenique C, Stalla GK, Holsboer F, Arzt E: Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs. Curr Drug Targets Immune Endocr Metabol Disord; 2005 Sep;5(3):259-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signaling processes in tumoral neuroendocrine pituitary cells as potential targets for therapeutic drugs.
  • Pituitary adenomas are neuroendocrine tumors that produce different endocrine and metabolic alterations, including hyperprolactinemia, acromegaly and Cushing's disease.
  • These different clinical features of pituitary tumors are the result of the overproduction of hormones produced by the different pituitary cell types.
  • Recent advances in the understanding of the signaling pathways that control hormone production in pituitary cells provide a source of potential therapeutic targets.
  • Therefore, the study of signaling pathways that control hormone production and proliferation is a good source of candidate targets in pituitary tumors.
  • [MeSH-major] Neurosecretory Systems / drug effects. Neurosecretory Systems / physiology. Pituitary Neoplasms / drug therapy. Pituitary Neoplasms / physiopathology. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16178787.001).
  • [ISSN] 1568-0088
  • [Journal-full-title] Current drug targets. Immune, endocrine and metabolic disorders
  • [ISO-abbreviation] Curr. Drug Targets Immune Endocr. Metabol. Disord.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cytokines; 0 / Receptors, Cytokine; 0 / Transforming Growth Factor beta; 9002-60-2 / Adrenocorticotropic Hormone; 9002-62-4 / Prolactin
  • [Number-of-references] 77
  •  go-up   go-down


44. Rix M, Laurberg P, Hoejberg AS, Brock-Jacobsen B: Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl. Eur J Endocrinol; 2005 Aug;153(2):195-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
  • We aimed to describe the results of pegvisomant therapy in a 12-year-old girl with an aggressive GH-secreting pituitary tumour.
  • DESIGN: To evaluate the ability of pegvisomant therapy to control the effects of peripheral GH excess in a case of pituitary gigantism.
  • RESULTS: A large pituitary adenoma with suprasellar extension was diagnosed in a 12-year-old girl with progressive tall stature (178 cm), GH hypersecretion without suppression during oral glucose loading (nadir serum GH, 90 mU/l), high serum IGF-I and serum prolactin levels.
  • Histological examination showed a mixed GH- and prolactin-secreting adenoma with lymphocytic infiltration of B and T cells.
  • CONCLUSIONS: We suggest that treatment in pituitary gigantism with pegvisomant is safe and may normalize IGF-I levels and effectively stop growing.

  • Genetic Alliance. consumer health - Gigantism.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061823.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Somatotropin; 0 / pegvisomant; 12629-01-5 / Human Growth Hormone; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


45. Ballian N, Chrisoulidou A, Nomikos P, Samara C, Kontogeorgos G, Kaltsas GA: Hypophysitis superimposed on a non-functioning pituitary adenoma: diagnostic clinical, endocrine, and radiologic features. J Endocrinol Invest; 2007 Sep;30(8):677-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypophysitis superimposed on a non-functioning pituitary adenoma: diagnostic clinical, endocrine, and radiologic features.
  • Pituitary adenomas are common neoplasms requiring medical and/or surgical treatment when associated with hormonal hypersecretion.
  • Treatment of non-functioning pituitary adenomas is necessary when symptoms of mass effect or hormonal deficits occur.
  • Hence, it is important to consider disorders that could present in a similar manner to pituitary adenomas, for which surgery is not the indicated therapeutic approach.
  • We describe herein a 38-yr-old woman who presented with a pituitary lesion that was considered to be a non-functioning pituitary adenoma.
  • Fifteen months after initial diagnosis, considerable enlargement of the lesion was noted, extending mainly superiorly and indenting the optic chiasm.
  • Repeated endocrine investigation revealed partial anterior pituitary insufficiency.
  • The patient underwent trans-sphenoidal resection of the pituitary lesion; histology revealed a null cell pituitary adenoma and lymphocytic hypophysitis (LYH) of the non-neoplastic adenohypophysial gland.
  • Post-operatively, complete anterior and partial posterior pituitary insufficiency developed.
  • This case illustrates the effects of new-onset LYH in a patient with a pre-existing non-functioning pituitary adenoma.
  • Being aware of this rare possibility is important, as enlargement of the pituitary lesion may not be caused by expansion of the preexisting tumor, but by the onset of LYH of the nonneoplastic pituitary tissue.
  • [MeSH-major] Adenoma / pathology. Hypopituitarism / pathology. Inflammation. Magnetic Resonance Imaging. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Pituitary Hormones / metabolism

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 1998 Jun;45(3):357-61 [9790270.001]
  • [Cites] Neurosurgery. 1995 May;36(5):1016-9 [7791966.001]
  • [Cites] Ann Med Interne (Paris). 1999 Jun;150(4):327-41 [10519020.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Mar;86(3):1048-53 [11238484.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):713-22; discussion 722-3 [9092844.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):3859-66 [10566620.001]
  • [Cites] Acta Neuropathol. 1995;90(6):637-44 [8615086.001]
  • [Cites] Radiology. 1995 Apr;195(1):30-4 [7892490.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Aug;80(8):2302-11 [7629223.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):599-614 [15634713.001]
  • [Cites] Medicine (Baltimore). 1989 Jul;68(4):240-56 [2661963.001]
  • [Cites] Neuroradiology. 1998 Feb;40(2):114-20 [9541922.001]
  • [Cites] Neurol India. 2003 Dec;51(4):461-5 [14742922.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):609-18 [9467582.001]
  • [Cites] Eur J Endocrinol. 2003 Nov;149(5):363-76 [14585081.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):650-4 [12574195.001]
  • [Cites] Endocr J. 1993 Aug;40(4):431-8 [7920896.001]
  • [Cites] J Reprod Med. 1995 Apr;40(4):251-9 [7623353.001]
  • [Cites] Clin Endocrinol (Oxf). 1995 Mar;42(3):315-22 [7758238.001]
  • [Cites] Endocr Relat Cancer. 2001 Dec;8(4):287-305 [11733226.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):752-7 [11836316.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3455-9 [8855784.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jul;91(7):2484-9 [16621907.001]
  • [Cites] J Neuroradiol. 2002 Mar;29(1):57-60 [11984480.001]
  • [Cites] Endocr J. 2003 Dec;50(6):697-702 [14709840.001]
  • [Cites] J Neurosurg. 2004 Aug;101(2):262-71 [15309917.001]
  • [Cites] Eur J Endocrinol. 2001 Jun;144(6):569-75 [11375790.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):604-7 [17090639.001]
  • (PMID = 17923800.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Pituitary Hormones
  •  go-up   go-down


46. Ruggeri RM, Santarpia L, Curtò L, Torre ML, Galatioto M, Galatioto S, Trimarchi F, Cannavò S: Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations. J Endocrinol Invest; 2008 Nov;31(11):946-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations.
  • BACKGROUND: Mutations of the genes encoding the alpha subunit of the stimulatory G protein (Gs) and of the inhibiting Gi2 protein (GNAS1 and GNAI2 genes, respectively) have been described in various endocrine neoplasias, including pituitary tumors.
  • AIM: To search for mutations of GNAS1 and GNAI2 in a continuous series of non-functioning pituitary adenoma (NFPA) patients neurosurgically treated.
  • [MeSH-major] Adenoma, Acidophil / genetics. Adenoma, Chromophobe / genetics. GTP-Binding Protein alpha Subunits, Gs / genetics. Intracellular Signaling Peptides and Proteins / genetics. Pituitary Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Endocrinol. 1997 Nov;137(5):482-9 [9405027.001]
  • [Cites] Pituitary. 2003 Sep;6(2):75-80 [14703016.001]
  • [Cites] Eur J Clin Invest. 1995 Feb;25(2):128-31 [7737262.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Jan;52(1):35-42 [10651751.001]
  • [Cites] J Am Soc Nephrol. 2006 Apr;17(4 Suppl 2):S115-9 [16565233.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Dec;71(6):1427-33 [1977759.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jan;93(1):278-84 [17989125.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):336-40 [1973174.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Sep;79(3):890-3 [8077378.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):836-49 [12415254.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Sep;77(3):765-9 [8396579.001]
  • [Cites] J Endocrinol. 1998 May;157(2):177-86 [9659280.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Dec;71(6):1421-6 [1977758.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Dec;71(6):1416-20 [2121775.001]
  • [Cites] Clin Endocrinol (Oxf). 1994 Dec;41(6):815-20 [7889619.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Oct;228(9):1004-17 [14530508.001]
  • (PMID = 19169048.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Chromogranins; 0 / Codon; 0 / Intracellular Signaling Peptides and Proteins; 0 / URI1 protein, human; EC 3.6.1.- / GNAS protein, human; EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


47. Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K: Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome. Endocr Pathol; 2010 Dec;21(4):227-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.
  • The aim of the present study was to assess immunohistochemical expression of MGMT in ACTH-secreting pituitary adenomas of patients with Nelson syndrome.
  • Our material consisted of eight specimens from ACTH-secreting pituitary adenomas of patients with Nelson syndrome.
  • Absent or low MGMT staining in brain and other neoplasms has been shown to correlate with successful treatment with temozolomide, and recent reports of aggressive pituitary adenomas suggest similar outcomes.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / metabolism. Adenoma / metabolism. DNA Modification Methylases / biosynthesis. DNA Repair Enzymes / biosynthesis. Nelson Syndrome / metabolism. Tumor Suppressor Proteins / biosynthesis

  • Genetic Alliance. consumer health - Nelson syndrome.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12 ):1470-5 [17442989.001]
  • [Cites] Clin Endocrinol (Oxf). 2006 Oct;65(4):552-3 [16984254.001]
  • [Cites] Clin Endocrinol (Oxf). 2009 Aug;71(2):226-33 [19067722.001]
  • [Cites] Hormones (Athens). 2009 Oct-Dec;8(4):303-6 [20045804.001]
  • [Cites] Anticancer Agents Med Chem. 2008 May;8(4):368-80 [18473722.001]
  • [Cites] Virchows Arch. 2001 Jun;438(6):595-602 [11469692.001]
  • [Cites] J Clin Oncol. 2006 Jul 20;24(21):3431-7 [16849758.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):185-9 [17056093.001]
  • [Cites] Acta Neuropathol. 2008 Feb;115(2):261-2 [17926052.001]
  • [Cites] Eur J Endocrinol. 2009 Jan;160(1):115-9 [18984772.001]
  • [Cites] Neurosurgery. 2009 Apr;64(4):E773-4; discussion E774 [19349807.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Neurosurg Focus. 2007;23(3):E13 [17961028.001]
  • [Cites] Jpn J Clin Oncol. 2007 Dec;37(12 ):897-906 [18156172.001]
  • (PMID = 21061089.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  •  go-up   go-down


48. Lupi I, Manetti L, Caturegli P, Menicagli M, Cosottini M, Iannelli A, Acerbi G, Bevilacqua G, Bogazzi F, Martino E: Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma. J Clin Endocrinol Metab; 2010 Jan;95(1):289-96
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.
  • CONTEXT: Serum pituitary antibodies (Pit Abs) and tumor-infiltrating lymphocytes (TILs) have been described in pituitary adenomas, but their clinical significance remains unknown.
  • OBJECTIVE: The objective of the study was to assess Pit Abs and TILs prevalence in pituitary adenomas and their influence on clinical outcome.
  • PATIENTS AND SETTING: Two hundred ninety-one pituitary adenoma cases (110 non-secreting, 30 ACTH-69 GH-71 prolactin- and 13 TSH-secreting adenoma; 177 operated and 114 untreated), 409 healthy controls, and 14 autoimmune hypophysitis were enrolled in a tertiary referral center.
  • The presence of TILs was evaluated using CD45 staining in a subset of adenomas surgically treated (n = 72).
  • MAIN OUTCOME MEASURE: Clinical response of pituitary adenoma after surgery was evaluated.
  • RESULTS: Pit Abs prevalence was higher in adenomas (5.1%) than healthy subjects (0.7%, P < 0.0001) and lower than in autoimmune hypophysitis patients (57%, P < 0.0001).
  • Similarly, TILs prevalence was higher in adenomas than normal pituitary (P = 0.01) and lower than in autoimmune hypophysitis (P < 0.0001).
  • A poor clinical outcome was more common in adenoma patients with TILs (11 of 18, 61%) than in those without (17 of 54, 31%, P = 0.026).
  • Multivariate regression analysis identified the presence of TILs as independent prognostic factor for persistence/recurrence of pituitary adenoma.
  • CONCLUSIONS: TILs and Pit Abs are present in a significant number of pituitary adenoma patients.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Horm Res. 2001;55(6):288-92 [11805433.001]
  • [Cites] Pituitary. 2011 Dec;14(4):388-94 [19466616.001]
  • [Cites] Eur J Cancer. 2002 Oct;38(15):2014-9 [12376206.001]
  • [Cites] J Endocrinol. 2002 Nov;175(2):417-23 [12429039.001]
  • [Cites] Eur J Endocrinol. 2002 Dec;147(6):767-75 [12457452.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Feb;88(2):650-4 [12574195.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]
  • [Cites] Endocr J. 2003 Dec;50(6):697-702 [14709840.001]
  • [Cites] Endocrine. 2003 Dec;22(3):335-40 [14709807.001]
  • [Cites] Lancet. 1987 Jun 20;1(8547):1394-8 [2884495.001]
  • [Cites] J Clin Endocrinol Metab. 1988 Oct;67(4):633-8 [3417843.001]
  • [Cites] J Endocrinol Invest. 1991 Sep;14(8):691-6 [1774454.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 May;38(5):495-500 [8080469.001]
  • [Cites] Acta Neurochir (Wien). 1994;126(1):38-43 [8154320.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Dec;80(12):3421-4 [8530576.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):609-18 [9467582.001]
  • [Cites] J Lab Clin Med. 1998 Jul;132(1):25-31 [9665368.001]
  • [Cites] Endocr J. 1998 Jun;45(3):357-61 [9790270.001]
  • [Cites] Endocr Rev. 2005 Aug;26(5):599-614 [15634713.001]
  • [Cites] J Neurosurg. 2006 Aug;105(2):309-14 [17219839.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Feb;92(2):604-7 [17090639.001]
  • [Cites] Neurol Med Chir (Tokyo). 2007 Mar;47(3):136-9 [17384498.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):513-9 [17409910.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jun;92(6):2176-81 [17341554.001]
  • [Cites] Ann N Y Acad Sci. 2007 Jun;1107:129-35 [17804540.001]
  • [Cites] J Endocrinol Invest. 2007 Sep;30(8):677-83 [17923800.001]
  • [Cites] Neurosurg Rev. 2008 Apr;31(2):157-63 [18253771.001]
  • [Cites] Endocr J. 2000 Aug;47(4):407-16 [11075721.001]
  • [Cites] Immunol Rev. 2008 Apr;222:101-16 [18363996.001]
  • [Cites] Immunol Rev. 2008 Apr;222:328-40 [18364012.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 May-Jun;56(3):181-91 [18512029.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Aug;69(2):269-78 [18194487.001]
  • [Cites] Endocr J. 2008 Aug;55(4):729-35 [18497455.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1661-6 [18753941.001]
  • [Cites] Histochem Cell Biol. 2008 Dec;130(6):1079-90 [18953558.001]
  • [Cites] Cancer Immun. 2008;8:16 [19053167.001]
  • [Cites] Cancer Lett. 2009 Jun 18;278(2):123-9 [18930343.001]
  • [Cites] No Shinkei Geka. 2002 Jan;30(1):95-9 [11806114.001]
  • (PMID = 19875479.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R21 DK080351; United States / NIDDK NIH HHS / DK / DK080351
  • [Publication-type] Evaluation Studies; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers
  • [Other-IDs] NLM/ PMC2805498
  •  go-up   go-down


49. Dahlqvist P, Koskinen LO, Brännström T, Hägg E: Testicular enlargement in a patient with a FSH-secreting pituitary adenoma. Endocrine; 2010 Apr;37(2):289-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular enlargement in a patient with a FSH-secreting pituitary adenoma.
  • Clinically non-functional pituitary adenomas are often derived from gonadotropin producing cells.
  • Magnetic resonance imaging (MRI) and biochemical examinations showed a large pituitary adenoma and excessive levels of serum FSH.
  • After pituitary surgery, serum FSH levels normalized and there was a decrease in testicular volume.
  • This is in line with experimental studies showing biological effect of FSH from pituitary adenomas and previous occasional reports of ovarian hyperstimulation and testicular enlargement in patients with FSH-secreting gonadotropinomas.
  • [MeSH-major] Adenoma / pathology. Adenoma / secretion. Follicle Stimulating Hormone / secretion. Pituitary Neoplasms / pathology. Pituitary Neoplasms / secretion. Testis / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Reprod Med. 2002 Nov;20(4):339-48 [12536357.001]
  • [Cites] Semin Reprod Med. 2004 Aug;22(3):177-85 [15319820.001]
  • [Cites] Endocrine. 1999 Dec;11(3):205-15 [10786817.001]
  • [Cites] J Endocrinol Invest. 1998 Jun;21(6):372-9 [9699129.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Oct;31(4):411-23 [2627747.001]
  • [Cites] Endocrinology. 2003 Feb;144(2):509-17 [12538611.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Oct;71(4):907-12 [2119391.001]
  • [Cites] Cancer Treat Res. 1997;89:57-72 [9204188.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2008 Apr;4(4):234-8 [18268519.001]
  • [Cites] Endocr Rev. 1985 Fall;6(4):552-63 [2416559.001]
  • [Cites] Acta Genet Stat Med. 1951;2(Suppl. 1):1-166 [15444009.001]
  • [Cites] Andrologia. 1995 Jul-Aug;27(4):207-12 [7486030.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Mar;38(3):301-9 [8458102.001]
  • [Cites] Mol Endocrinol. 2002 Dec;16(12):2780-92 [12456799.001]
  • [Cites] Mt Sinai J Med. 1982 Jul-Aug;49(4):297-304 [6813681.001]
  • [Cites] Endocrinology. 2004 Jan;145(1):318-29 [14551232.001]
  • (PMID = 20960265.001).
  • [ISSN] 1559-0100
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


50. Rocque BG, Herold KA, Salamat MS, Shenker Y, Kuo JS: Symptomatic hyperprolactinemia from an ectopic pituitary adenoma located in the clivus. Endocr Pract; 2009 Mar;15(2):143-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic hyperprolactinemia from an ectopic pituitary adenoma located in the clivus.
  • OBJECTIVE: To report a case of an ectopic pituitary adenoma in the clivus.
  • METHODS: The clinical, laboratory, and imaging findings of the case are reviewed, and the embryogenesis of the pituitary gland, the pathophysiologic features of this condition, the diagnosis, and the treatment options are discussed.
  • After the resected tissue was examined, the patient was diagnosed as having an ectopic prolactin-producing pituitary adenoma.
  • Surgical resection was undertaken in our patient because of the uncertainty of the diagnosis and the aggressive natural history of more common tumors of the clivus, such as chordomas.
  • Although it is possible that a successful trial of dopaminergic therapy would have obviated surgical intervention, this approach would be associated with additional risks if the diagnosis were incorrect.
  • [MeSH-major] Cranial Fossa, Posterior / pathology. Hyperprolactinemia / diagnosis. Hyperprolactinemia / pathology. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Galactorrhoea-Hyperprolactinaemia.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289326.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, Degli Uberti EC: Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab; 2010 Feb;95(2):968-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of everolimus on cell viability in nonfunctioning pituitary adenomas.
  • CONTEXT: Pituitary adenomas can cause specific syndromes due to hormone excess and/or determine sellar mass symptoms.
  • Pituitary cell growth can sometimes be influenced by medical therapy, such as for somatotroph adenomas treated with somatostatin analogs or prolactinomas treated with dopaminergic drugs.
  • However, nonfunctioning pituitary adenomas (NFAs) are still orphans of medical therapy.
  • Somatostatin and dopamine subtype 2 receptor expression was investigated by quantitative PCR.
  • [MeSH-major] Adenoma / drug therapy. Immunosuppressive Agents / pharmacology. Pituitary Neoplasms / drug therapy. Sirolimus / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965918.001).
  • [ISSN] 1945-7197
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ergolines; 0 / Immunosuppressive Agents; 0 / Receptors, Somatostatin; 0 / Vascular Endothelial Growth Factor A; 0 / somatostatin receptor 2; 51110-01-1 / Somatostatin; 98H1T17066 / pasireotide; 9HW64Q8G6G / Everolimus; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; LL60K9J05T / cabergoline; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


52. Buchfelder M, Schlaffer S: Pituitary surgery for Cushing's disease. Neuroendocrinology; 2010;92 Suppl 1:102-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary surgery for Cushing's disease.
  • Transsphenoidal surgery is considered the treatment of choice in most patients with Cushing's disease once the diagnosis has been established.
  • Usually, a selective adenomectomy is attempted, preserving pituitary functions.
  • However, the outcome of these procedures is less favorable than with selective resections of distinct adenomas.
  • Less than 10% of pituitary adenomas associated with Cushing's disease are macroadenomas.
  • A close cooperation with the endocrinologist is mandatory for a neurosurgeon operating on patients with Cushing's disease, namely for the pre- and perioperative care and for long-term follow-up.
  • [MeSH-major] Adenoma / surgery. Hypophysectomy / methods. Pituitary ACTH Hypersecretion / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Humans. Pituitary Gland / surgery. Sella Turcica / surgery


53. Erem C, Ersöz HO, Ukinç K, Avunduk AM, Hacihasanoglu A, Koçak M: Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine; 2006 Aug;30(1):145-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging disclosed the presence of a pituitary adenoma.
  • Pituitary adenoma was removed surgically.
  • [MeSH-major] Acromegaly / complications. Adenoma / complications. Diabetic Ketoacidosis / complications. Growth Hormone-Secreting Pituitary Adenoma / complications. Retinitis Pigmentosa / complications

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Retinitis pigmentosa.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Postgrad Med J. 1996 Nov;72(853):682-3 [8944212.001]
  • [Cites] Endocr Pract. 2004 May-Jun;10(3):213-25 [15382339.001]
  • [Cites] Br Heart J. 1985 Feb;53(2):153-7 [2857086.001]
  • [Cites] J Endocrinol Invest. 1996 Oct;19(9):647-8 [8957752.001]
  • [Cites] Int J Clin Pract. 1997 Oct;51(7):476-7 [9536592.001]
  • [Cites] Med Sci Monit. 2001 Jan-Feb;7(1):142-7 [11208511.001]
  • [Cites] Lancet. 1990 Aug 4;336(8710):318-9 [1974009.001]
  • [Cites] Clin Pharm. 1989 Apr;8(4):255-73 [2653711.001]
  • [Cites] Liver. 1995 Oct;15(5):236-41 [8531592.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Oct;82(10):3308-14 [9329359.001]
  • [Cites] Intern Med. 1997 May;36(5):345-50 [9213172.001]
  • [Cites] Pharmacotherapy. 1998 Mar-Apr;18(2):413-6 [9545165.001]
  • [Cites] J Endocrinol Invest. 1993 Dec;16(11):857-61 [8144862.001]
  • [Cites] Hepatology. 1995 May;21(5):1255-60 [7737631.001]
  • [Cites] Braz J Med Biol Res. 2001 Nov;34(11):1429-33 [11668352.001]
  • [Cites] Br J Ophthalmol. 1972 Jan;56(1):25-31 [5058713.001]
  • [Cites] Doc Ophthalmol. 1999;98(2):175-81 [10947002.001]
  • [Cites] Anesth Analg. 2004 Feb;98(2):318-20, table of contents [14742361.001]
  • [Cites] Cardiovasc Res. 2001 Jan;49(1):27-37 [11121793.001]
  • [Cites] Endocr Rev. 2004 Feb;25(1):102-52 [14769829.001]
  • [Cites] Endocr J. 1995 Dec;42(6):739-45 [8822314.001]
  • [Cites] Endocr Pract. 2000 Nov-Dec;6(6):450-2 [11155217.001]
  • [Cites] Diabetes Care. 1979 May-Jun;2(3):296-306 [116831.001]
  • [Cites] Clin Endocrinol (Oxf). 1987 Apr;26(4):481-512 [3308190.001]
  • (PMID = 17185803.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; RWM8CCW8GP / Octreotide
  •  go-up   go-down


54. Isidro ML, Iglesias Díaz P, Matías-Guiu X, Cordido F: Acromegaly due to a growth hormone-releasing hormone-secreting intracranial gangliocytoma. J Endocrinol Invest; 2005 Feb;28(2):162-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In more than 95% of cases acromegaly is due to GH hypersecretion by a pituitary adenoma.
  • In cases of intrasellar gangliocytomas, not even radiological findings help to make the correct diagnosis, which can only be made with the hystological study.
  • Histopathological diagnosis was consistent with gangliocytoma, and immunostaining in the ganglionic cells was positive for GHRH.
  • Clinical and biochemical data did not allow to make the correct diagnosis, which was only made on the pathological study.
  • This case underscores that acromegaly can be due to causes other than a GH-secreting adenoma, and underlines that finding an image not typical of a pituitary adenoma should raise the suspicion that an unusual cause subsides the acromegaly.

  • Genetic Alliance. consumer health - Acromegaly.
  • Genetic Alliance. consumer health - Gangliocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] J Clin Endocrinol Metab. 1984 May;58(5):796-803 [6423659.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):490-5 [10470826.001]
  • [Cites] Clin Endocrinol (Oxf). 1997 Aug;47(2):123-35 [9302383.001]
  • [Cites] Brain Tumor Pathol. 2002;19(2):63-7 [12622135.001]
  • [Cites] Arch Intern Med. 2001 Apr 9;161(7):1010-1 [11295968.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):607-13 [10757410.001]
  • [Cites] Exp Clin Endocrinol Diabetes. 1995;103(3):129-49 [7584515.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S131-4 [11762340.001]
  • (PMID = 15887863.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 0G3DE8943Y / lanreotide; 51110-01-1 / Somatostatin; 9034-39-3 / Growth Hormone-Releasing Hormone
  •  go-up   go-down


55. Davis JR, McNeilly JR, Norris AJ, Pope C, Wilding M, McDowell G, Holland JP, McNeilly AS: Fetal gonadotrope cell origin of FSH-secreting pituitary adenoma - insight into human pituitary tumour pathogenesis. Clin Endocrinol (Oxf); 2006 Nov;65(5):648-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fetal gonadotrope cell origin of FSH-secreting pituitary adenoma - insight into human pituitary tumour pathogenesis.
  • OBJECTIVE: The pathogenesis of human pituitary adenomas remains unclear, but we report a case of FSH-secreting pituitary adenoma whose monohormonal phenotype suggests it was of fetal origin.
  • MEASUREMENTS: Endocrine studies were performed before and after curative surgery, with assessment of tumour hormone secretion in vitro, and immunostaining of tumour tissue for a series of gonadotrope proteins.
  • Human fetal pituitary tissue contained FSH-only cells at 18 weeks gestation, whereas normal adult pituitary tissue contained only bihormonal gonadotropes.
  • CONCLUSIONS: We propose that this pituitary adenoma represents an indolent tumour of monohormonal fetal gonadotrope cells that originated early in gestation.
  • Pituitary tumours may therefore arise from abnormal persistence of fetal cell types, with extremely slow growth over many years until reaching a size threshold to generate an endocrine syndrome.
  • Understanding fetal pituitary architecture and function may be more informative for new insights into pituitary tumour pathogenesis than classical theories of cancer biology that invoke unrestrained cell proliferation.
  • [MeSH-major] Adenoma / embryology. Gonadotrophs / secretion. Pituitary Neoplasms / embryology
  • [MeSH-minor] Adult. Estradiol / blood. Female. Follicle Stimulating Hormone / analysis. Follicle Stimulating Hormone / blood. Follicle Stimulating Hormone / secretion. Humans. Immunohistochemistry / methods. Immunoradiometric Assay / methods. Luteinizing Hormone / blood. Pituitary Gland, Anterior / embryology. Pituitary Gland, Anterior / secretion. Polycystic Ovary Syndrome / blood. Polycystic Ovary Syndrome / embryology. Polycystic Ovary Syndrome / etiology. Tissue Culture Techniques

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. The Antibody Registry: Reagent: Antibodies .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054468.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


56. Chuang CC, Chang CN, Wei KC, Liao CC, Hsu PW, Huang YC, Chen YL, Lai LJ, Pai PC: Surgical treatment for severe visual compromised patients after pituitary apoplexy. J Neurooncol; 2006 Oct;80(1):39-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for severe visual compromised patients after pituitary apoplexy.
  • BACKGROUND: Pituitary apoplexy is a rare neurovascular insult.
  • METHODS: Thirteen patients who presented with severe visual defect after pituitary apoplexy were enrolled retrospectively.
  • Six patients without severe underlying diseases were considered non-complicated and were treated early.
  • We postulated old age, underlying malignant diseases, and coagulation disorders played the predisposing factors of poor outcome in these cases.
  • [MeSH-major] Decompression, Surgical. Pituitary Apoplexy / complications. Pituitary Apoplexy / surgery. Vision, Low / etiology. Vision, Low / surgery
  • [MeSH-minor] Adenoma / complications. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Gland / blood supply. Pituitary Gland / pathology. Pituitary Neoplasms / complications. Pituitary Neoplasms / surgery. Prognosis. Recovery of Function. Retrospective Studies. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroophthalmol. 2004 Mar;24(1):31-3 [15206436.001]
  • [Cites] Acta Anaesthesiol Scand. 1999 Feb;43(2):236-8 [10027037.001]
  • [Cites] J Neurosurg. 1983 Mar;58(3):315-20 [6827315.001]
  • [Cites] J Neurosurg. 1972 Jan;36(1):83-5 [5007273.001]
  • [Cites] Neurosurgery. 1993 Oct;33(4):602-8; discussion 608-9 [8232799.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Dec;61(6):747-52 [15579190.001]
  • [Cites] Br J Neurosurg. 1995 Apr;9(2):151-7 [7632360.001]
  • [Cites] J Neurosurg. 1981 Aug;55(2):187-93 [7252541.001]
  • [Cites] Expert Opin Pharmacother. 2004 Jun;5(6):1287-98 [15163274.001]
  • [Cites] Neurosurg Focus. 2004 Apr 15;16(4):E6 [15191335.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Oct;71(4):542-5 [11561045.001]
  • [Cites] Growth Horm IGF Res. 2005 Jul;15 Suppl A:S36-41 [16039890.001]
  • [Cites] Cerebrovasc Dis. 2006;21(1-2):142-4 [16374004.001]
  • [Cites] Am J Cardiol. 1998 Jan 1;81(1):110-1 [9462623.001]
  • [Cites] Acta Neurochir (Wien). 2004 Nov;146(11):1275-6 [15503190.001]
  • [Cites] J Am Optom Assoc. 1984 May;55(5):359-61 [6725833.001]
  • [Cites] Neurosurgery. 2005;56(1):65-72; discussion 72-3 [15617587.001]
  • [Cites] Surg Neurol. 2005 Jan;63(1):42-6; discussion 46 [15639521.001]
  • [Cites] Neurosurgery. 2005 Feb;56(2):249-56; discussion 249-56 [15670373.001]
  • [Cites] Acta Neurochir (Wien). 2001;143(3):303-6; discussion 306-7 [11460919.001]
  • [Cites] J Neurosurg Sci. 1999 Mar;43(1):25-36 [10494663.001]
  • [Cites] Endocr Pract. 1999 Sep-Oct;5(5):273-6 [15251667.001]
  • [Cites] Leg Med (Tokyo). 2001 Sep;3(3):183-6 [12935525.001]
  • [Cites] BMJ. 1994 Nov 26;309(6966):1408 [7755711.001]
  • [Cites] Acta Neurochir (Wien). 2005 Feb;147(2):151-7; discussion 157 [15570437.001]
  • [Cites] Anaesthesia. 1992 Mar;47(3):234-6 [1566994.001]
  • [Cites] Neurosurgery. 1984 Mar;14(3):363-73 [6369168.001]
  • [Cites] World J Surg. 1982 Nov;6(6):686-8 [7180002.001]
  • [Cites] Anesthesiology. 1998 Dec;89(6):1580-2 [9856739.001]
  • [Cites] J Endocrinol Invest. 1999 Oct;22(9):698-700 [10595834.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jul;80(7):2190-7 [7608278.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1996 Apr;122(4):389-92 [8600923.001]
  • [Cites] Am J Emerg Med. 2000 May;18(3):328-31 [10830692.001]
  • [Cites] South Med J. 2002 Apr;95(4):469-70 [11958251.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Aug;51(2):181-8 [10468988.001]
  • (PMID = 16645717.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Ramakrishna N: The role of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas. Nat Clin Pract Endocrinol Metab; 2008 Mar;4(3):138-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212762.001).
  • [ISSN] 1745-8374
  • [Journal-full-title] Nature clinical practice. Endocrinology & metabolism
  • [ISO-abbreviation] Nat Clin Pract Endocrinol Metab
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


58. Georgitsi M, Heliövaara E, Paschke R, Kumar AV, Tischkowitz M, Vierimaa O, Salmela P, Sane T, De Menis E, Cannavò S, Gündogdu S, Lucassen A, Izatt L, Aylwin S, Bano G, Hodgson S, Koch CA, Karhu A, Aaltonen LA: Large genomic deletions in AIP in pituitary adenoma predisposition. J Clin Endocrinol Metab; 2008 Oct;93(10):4146-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large genomic deletions in AIP in pituitary adenoma predisposition.
  • CONTEXT: Germline mutations in AIP have been recently shown to cause pituitary adenoma predisposition (PAP).
  • DESIGN: Here, we applied the multiplex ligation-dependent probe amplification assay to examine whether large genomic AIP or MEN1 alterations account for a subset of PAP cases.
  • PATIENTS: The study was performed on familial and sporadic pituitary adenoma cases of European origin, which had previously tested negative for germline AIP and MEN1 mutations by sequencing.
  • RESULTS: Two of 21 pituitary adenoma families (9.5%) were found to harbor an AIP deletion.
  • No copy number changes were detected among 67 sporadic pituitary adenoma patients.
  • CONCLUSIONS: The present study shows that large genomic AIP deletions account for a subset of PAP.
  • [MeSH-major] Adenoma / genetics. Gene Deletion. Genetic Predisposition to Disease. Intracellular Signaling Peptides and Proteins / genetics. Pituitary Neoplasms / genetics. Precancerous Conditions / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628514.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU872273/ EU872274
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / aryl hydrocarbon receptor-interacting protein
  •  go-up   go-down


59. Kalfa N, Lumbroso S, Boulle N, Guiter J, Soustelle L, Costa P, Chapuis H, Baldet P, Sultan C: Activating mutations of Gsalpha in kidney cancer. J Urol; 2006 Sep;176(3):891-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Activating Gsalpha mutations have been reported in tumors arising only from highly specialized endocrine tissue, such as pituitary adenomas, toxic thyroid adenomas and differentiated thyroid carcinomas, but never in other nonendocrine tumors.

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890646.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.6.5.1 / GTP-Binding Protein alpha Subunits, Gs
  •  go-up   go-down


60. Tamasauskas A, Sinkūnas K, Draf W, Deltuva V, Matukevicius A, Rastenyte D, Vaitkus S: Management of cerebrospinal fluid leak after surgical removal of pituitary adenomas. Medicina (Kaunas); 2008;44(4):302-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cerebrospinal fluid leak after surgical removal of pituitary adenomas.
  • METHODS: During the period from 1995 to 2005, 313 patients underwent 356 transsphenoidal operations for pituitary adenoma.
  • RESULTS: Adenoma was totally removed in 198 (55.6%) cases out of 356.
  • [MeSH-major] Adenoma / surgery. Cerebrospinal Fluid Rhinorrhea / surgery. Pituitary Neoplasms / surgery. Postoperative Complications / surgery. Prolactinoma / surgery. Sella Turcica / surgery. Sphenoid Sinus / surgery
  • [MeSH-minor] ACTH-Secreting Pituitary Adenoma / surgery. Aged. Bone Transplantation. Cellulose, Oxidized / therapeutic use. Drug Combinations. Female. Fibrinogen / therapeutic use. Follow-Up Studies. Humans. Intraoperative Complications. Male. Middle Aged. Surgical Sponges. Thrombin / therapeutic use. Time Factors

  • Genetic Alliance. consumer health - Cerebrospinal Fluid Leak.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469507.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Cellulose, Oxidized; 0 / Drug Combinations; 0 / TachoSil; 82347-53-3 / Surgicel; 9001-32-5 / Fibrinogen; EC 3.4.21.5 / Thrombin
  •  go-up   go-down


61. Lanfranco F, Baldi M, Cassoni P, Bosco M, Ghé C, Muccioli G: Ghrelin and prostate cancer. Vitam Horm; 2008;77:301-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several endocrine and nonendocrine cancer cells (pituitary adenomas; gastroenteropancreatic and pulmonary carcinoids; colorectal neoplasms, thyroid tumors; lung, breast, and pancreatic carcinomas) as well as their related cell lines have been shown able to express ghrelin both at mRNA and at protein level.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17983862.001).
  • [ISSN] 0083-6729
  • [Journal-full-title] Vitamins and hormones
  • [ISO-abbreviation] Vitam. Horm.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Receptors, Ghrelin
  • [Number-of-references] 130
  •  go-up   go-down


62. Levy MJ, Classey JD, Maneesri S, Meeran K, Powell M, Goadsby PJ: The relationship between neuropeptide Y expression and headache in pituitary tumours. Eur J Neurol; 2006 Feb;13(2):125-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between neuropeptide Y expression and headache in pituitary tumours.
  • Patients with pituitary tumours often present with disabling headache but there is no clear relationship between tumour size and headache.
  • Neuropeptide Y (NPY) has been identified in pituitary tumours and may serve as a biochemical marker of the propensity for headache.
  • Using immunohistochemical techniques we examined 27 consecutive pituitary adenoma specimens for NPY (including one normal postmortem control anterior pituitary specimen).
  • NPY positive immunoreactivity was seen in 13 tumour specimens (50%, 13 of 26 pituitary tumour specimens), characterized by cytoplasmic and nuclear staining patterns.
  • We did not observe NPY in the normal anterior pituitary control specimen.
  • NPY was present in four of five (80%) growth hormone-secreting tumours and two of two (100%) prolactinomas, compared with four of 11 (36%) non-functioning adenomas.
  • The mechanism of many pituitary tumour-associated headaches remains undetermined.
  • The significance of NPY positivity in pituitary tumours is unknown, although the results of this study may implicate this peptide in the control of somatotroph and lactotroph activity.
  • Our data do not support a clear role for NPY pituitary tumour-associated headache.
  • [MeSH-major] Headache / etiology. Headache / metabolism. Neuropeptide Y / metabolism. Pituitary Neoplasms / complications. Pituitary Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Headache.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490041.001).
  • [ISSN] 1351-5101
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neuropeptide Y
  •  go-up   go-down


63. Kalinin PL, Fomichev DV, Kutin MA, Kadashev BA, Faĭzullaev RB: [Extended endoscopic endonasal transsphenoidal approaches in skull base surgery]. Zh Vopr Neirokhir Im N N Burdenko; 2008 Oct-Dec;(4):47-9; discussion 49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pituitary adenomas and some other sellar tumors which traditionally require transcranial procedure now can be removed via endonasal route.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19230482.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


64. Sun C, Yamato T, Kondo E, Furukawa T, Ikeda H, Horii A: Infrequent mutation of APC, AXIN1, and GSK3B in human pituitary adenomas with abnormal accumulation of CTNNB1. J Neurooncol; 2005 Jun;73(2):131-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infrequent mutation of APC, AXIN1, and GSK3B in human pituitary adenomas with abnormal accumulation of CTNNB1.
  • We analyzed mutation of the APC, AXIN1, and GSK3genes in 14 pituitary adenomas with abnormal nuclear accumulations of CTNNB1.
  • Furthermore, the antibody for the C-terminus of APC detected normal expression of the APC protein in these pituitary adenomas.
  • Our present results imply that an unknown mechanism(s) accelerates the accumulation of CTNNB1 that plays an important role in the pathogenesis of human pituitary adenomas.
  • [MeSH-major] Adenoma / genetics. Adenomatous Polyposis Coli Protein / genetics. Cytoskeletal Proteins / metabolism. Glycogen Synthase Kinase 3 / genetics. Pituitary Neoplasms / genetics. Repressor Proteins / genetics. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Mol Carcinog. 1997 Aug;19(4):221-4 [9290697.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3231-3 [1317264.001]
  • [Cites] Cancer. 2001 Jan 1;91(1):42-8 [11148558.001]
  • [Cites] Genes Dev. 2000 Aug 1;14 (15):1837-51 [10921899.001]
  • [Cites] Cancer Res. 1998 Mar 15;58(6):1130-4 [9515795.001]
  • [Cites] Br J Cancer. 2000 May;82(10):1689-93 [10817505.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):422-6 [10201372.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1787-90 [9065402.001]
  • [Cites] J Endocrinol Invest. 2000 May;23(5):304-9 [10882148.001]
  • [Cites] Carcinogenesis. 2000 Jul;21(7):1453-6 [10874025.001]
  • [Cites] Genes Dev. 2000 Jul 15;14(14):1741-9 [10898789.001]
  • [Cites] Endocr Pathol. 1995 Autumn;6(3):189-196 [12114739.001]
  • [Cites] J Clin Endocrinol Metab. 1994 Jan;78(1):89-93 [8288721.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):443-53 [10862053.001]
  • [Cites] J Biochem. 1999 Apr;125(4):818-25 [10101297.001]
  • [Cites] Nat Genet. 2000 Mar;24(3):245-50 [10700176.001]
  • [Cites] Hum Mol Genet. 1992 Jul;1(4):229-33 [1338904.001]
  • [Cites] Jpn J Cancer Res. 1997 Nov;88(11):1025-8 [9439675.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Oct;17(2):88-93 [8913725.001]
  • [Cites] Endocr Relat Cancer. 2000 Mar;7(1):29-36 [10808194.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):243-8 [10679188.001]
  • [Cites] Science. 1997 Mar 21;275(5307):1790-2 [9065403.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):822-31 [1997855.001]
  • [Cites] Oncol Rep. 2004 Nov;12(5):1099-103 [15492799.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Br J Cancer. 1997;76(9):1119-23 [9365157.001]
  • (PMID = 15981102.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AXIN1 protein, human; 0 / Adenomatous Polyposis Coli Protein; 0 / Axin Protein; 0 / CTNNB1 protein, human; 0 / Cytoskeletal Proteins; 0 / Intercellular Signaling Peptides and Proteins; 0 / Repressor Proteins; 0 / Trans-Activators; 0 / Wnt Proteins; 0 / beta Catenin; EC 2.7.11.1 / GSK3B protein, human; EC 2.7.11.1 / Glycogen Synthase Kinase 3 beta; EC 2.7.11.26 / Glycogen Synthase Kinase 3
  •  go-up   go-down


65. Spallone A, Vidal RV, Gonzales JG: Transcranial approach to pituitary adenomas invading the cavernous sinus: A modification of the classical technique to be used in a low-technology environment. Surg Neurol Int; 2010;1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcranial approach to pituitary adenomas invading the cavernous sinus: A modification of the classical technique to be used in a low-technology environment.
  • OBJECTIVE: Pituitary adenomas invading the cavernous sinus represent a therapeutic challenge.
  • In relatively recent years, some authors have suggested a main direct surgical approach to cavernous sinus (CS) with the aim of complete removal of the adenoma, either by a modified trans-sphenoidal route, using or not an endoscopy-assisted approach, or by a transcranial direct approach.
  • MATERIALS AND METHODS: We report a technical modification of the classical epidural approach for CS adenoma removal.
  • Surgical technique included a fronto-orbito-zygomatic craniotomy with extradural anterior clinoidectomy, and intradural approach to the Hakuba's triangle for intracavernous dissection.
  • CONCLUSIONS: This experience, though limited, would suggest that the transcranial limited CS exposure through the Hakuba's triangle may allow adequate removal of intracavernous pituitary adenomas with very good long-term results and acceptable complication rate.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847907.001).
  • [ISSN] 2152-7806
  • [Journal-full-title] Surgical neurology international
  • [ISO-abbreviation] Surg Neurol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2940085
  • [Keywords] NOTNLM ; Cavernous sinus surgery / Hakuba’s triangle / fronto-orbito-zygomatic craniotomy (FOZ) / invasive adenoma / transcranial approach
  •  go-up   go-down


66. Pickett CA: Update on the medical management of pituitary adenomas. Curr Neurol Neurosci Rep; 2005 May;5(3):178-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on the medical management of pituitary adenomas.
  • The medical treatment of pituitary adenomas has changed significantly over the past decade.
  • Pharmacologic therapy for prolactinomas in the form of dopamine agonists has been available since the 1970s, and somatostatin analogues for treatment of growth hormone (GH)-secreting adenomas were introduced in the 1980s.
  • Furthermore, long-acting somatostatin analogues also have utility in treating thyrotropin adenomas and a subset of adrenocorticotroph tumors.
  • Limited clinical studies with long-acting dopamine agonists suggest that a subset of patients with GH, adrenocorticotroph, and gonadotropin/nonsecreting adenomas may also benefit from therapy with these agents.
  • This article highlights some of these evolving new ideas and approaches to the pharmacologic management of pituitary adenomas.
  • [MeSH-major] Adenoma / drug therapy. Dopamine Agonists / therapeutic use. Pituitary Neoplasms / drug therapy. Somatostatin / therapeutic use

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neth J Med. 2001 Dec;59(6):286-91 [11744180.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):495-500 [14764751.001]
  • [Cites] Pituitary. 2001 Aug;4(3):173-8 [12138990.001]
  • [Cites] Lancet. 2001 Nov 24;358(9295):1754-9 [11734231.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1381-8 [12727930.001]
  • [Cites] Endocr Rev. 2002 Oct;23 (5):623-46 [12372843.001]
  • [Cites] Expert Opin Investig Drugs. 2001 Sep;10 (9):1725-35 [11772281.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):223-40, viii [10207693.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1674-83 [15070930.001]
  • [Cites] Horm Res. 2003;60(2):53-60 [12876414.001]
  • [Cites] Trends Endocrinol Metab. 2001 Nov;12 (9):408-13 [11595543.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):19-21 [11849241.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Aug;85(8):2958-61 [10946911.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1222-6 [15001614.001]
  • [Cites] Ann Endocrinol (Paris). 2002 Apr;63(2 Pt 3):2S19-24 [12037499.001]
  • [Cites] J Clin Endocrinol Metab. 2004 May;89(5):2452-62 [15126577.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3099-102 [15240576.001]
  • [Cites] Drugs. 2004;64(16):1817-38 [15301564.001]
  • [Cites] Horm Res. 2004;62 Suppl 3:79-92 [15539805.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):65-71 [11849248.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 May;54(5):617-26 [11380492.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Mar;89(3):1131-9 [15001598.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):658-61 [14764777.001]
  • [Cites] Horm Res. 2000;53 Suppl 3:76-87 [10971110.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3142-7 [12107214.001]
  • [Cites] Endocr Rev. 1996 Dec;17(6):610-38 [8969971.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10 ):4759-67 [14557452.001]
  • [Cites] Curr Opin Investig Drugs. 2004 Oct;5(10 ):1072-9 [15535428.001]
  • [Cites] Eur J Endocrinol. 2004 Aug;151(2):173-8 [15296471.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Sep;51(3):281-4 [10469006.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Apr;52(4):437-45 [10762286.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):147-66 [12690986.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4709-19 [14557445.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Feb;85(2):526-9 [10690849.001]
  • [Cites] Endocr Relat Cancer. 2001 Dec;8(4):287-305 [11733226.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Aug;87(8):3537-42 [12161471.001]
  • [Cites] Eur J Nucl Med. 1999 Jan;26(1):46-50 [9933661.001]
  • [Cites] Neurosurg Clin N Am. 2003 Jan;14(1):81-7 [12690980.001]
  • [Cites] Neuroendocrinology. 2004;80 Suppl 1:57-61 [15477719.001]
  • [Cites] Pituitary. 2002;5(2):77-82 [12675504.001]
  • [Cites] Horm Res. 2004;62 Suppl 3:74-8 [15539804.001]
  • [Cites] Pituitary. 1999;1(2):115-20 [11081189.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jan;56(1):25-31 [11849243.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2849-53 [11397898.001]
  • [Cites] N Engl J Med. 2000 Apr 20;342(16):1171-7 [10770982.001]
  • [Cites] J Endocrinol Invest. 2004 May;27(5):RC8-11 [15279069.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):209-15 [15272916.001]
  • (PMID = 15865883.001).
  • [ISSN] 1528-4042
  • [Journal-full-title] Current neurology and neuroscience reports
  • [ISO-abbreviation] Curr Neurol Neurosci Rep
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Receptors, Somatotropin; 51110-01-1 / Somatostatin; 9002-72-6 / Growth Hormone
  • [Number-of-references] 50
  •  go-up   go-down


67. Rauch I, Kofler B: The galanin system in cancer. EXS; 2010;102:223-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of galanin peptide has been detected in pheochromocytoma, pituitary adenoma, neuroblastic tumours, gastrointestinal cancer, squamous cell carcinoma, brain tumours, melanoma, breast cancer and embryonal carcinoma.
  • Expression of peptide or receptors has been correlated with tumour stage or subtypes of pituitary adenoma, neuroblastic tumours, colon carcinoma and squamous cell carcinoma.
  • Galanin treatment has tumour-reducing effects in murine models of gastrointestinal cancer, whereas in animal experiments on adenoma formation, galanin seems to act as a growth factor, promoting both proliferation and tumour formation.
  • Therefore, galanin and its receptors are promising targets for diagnosis and treatment of several types of tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21299072.001).
  • [ISSN] 1023-294X
  • [Journal-full-title] EXS
  • [ISO-abbreviation] EXS
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 88813-36-9 / Galanin
  •  go-up   go-down


68. Fischli S, Jenni S, Allemann S, Zwahlen M, Diem P, Christ ER, Stettler C: Dehydroepiandrosterone sulfate in the assessment of the hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab; 2008 Feb;93(2):539-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dehydroepiandrosterone sulfate in the assessment of the hypothalamic-pituitary-adrenal axis.
  • CONTEXT: The role of dehydroepiandrosterone-sulfate (DHEA-S) in assessing the integrity of the hypothalamic-pituitary-adrenal (HPA) axis in patients with suspected insufficiency is uncertain.
  • OBJECTIVE: The objective of the study was to prospectively evaluate the diagnostic value of DHEA-S on HPA function in consecutive patients with suspected HPA insufficiency with and without pituitary lesions at a tertiary referral center.
  • In individuals with pituitary macroadenoma, a z-score below -2.0 had 100% specificity to predict HPA insufficiency (area under ROC curve 0.82).
  • In the absence of a pituitary adenoma, the diagnostic value of the z-score was reduced (area under ROC curve 0.71).
  • There is evidence that a z-score could be of diagnostic value in assessing HPA integrity, especially in younger patients and patients with pituitary macroadenoma, but further studies are needed to consolidate these findings.
  • [MeSH-major] Adrenal Insufficiency / blood. Dehydroepiandrosterone Sulfate / blood. Hypopituitarism / blood. Hypothalamic Diseases / blood. Hypothalamo-Hypophyseal System / physiopathology. Pituitary-Adrenal System / physiopathology

  • Bern Open Repository and Information System. Free Full text from BORIS .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986637.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Insulin; 57B09Q7FJR / Dehydroepiandrosterone Sulfate; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


69. Semple PL, Webb MK, de Villiers JC, Laws ER Jr: Pituitary apoplexy. Neurosurgery; 2005;56(1):65-72; discussion 72-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary apoplexy.
  • OBJECTIVE: Pituitary apoplexy is a rare yet potentially fatal disease.
  • We reviewed the combined experience of the University of Virginia in Charlottesville, VA, and Groote Schuur Hospital, University of Cape Town, South Africa, with 62 cases of pituitary apoplexy.
  • The average time of presentation was 14.2 days after the ictus, and 81% had no previous history of pituitary tumor.
  • CONCLUSION: Pituitary apoplexy is often misdiagnosed because the majority of patients have undetected pituitary adenomas, and the presentation is often mistaken for subarachnoid hemorrhage.
  • Most cases of pituitary apoplexy occur spontaneously, although precipitating factors have been suggested.
  • [MeSH-major] Pituitary Apoplexy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15617587.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Yan G, Hou R, Zhuang D, Chen L, Pang Q, Zhu J: Proteomic analysis of prolactinoma cells by immuno-laser capture microdissection combined with online two-dimensional nano-scale liquid chromatography/mass spectrometry. Proteome Sci; 2010 Jan 29;8:2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Pituitary adenomas, the third most common intracranial tumor, comprise nearly 16.7% of intracranial neoplasm and 25%-44% of pituitary adenomas are prolactinomas.
  • Prolactinoma represents a complex heterogeneous mixture of cells including prolactin (PRL), endothelial cells, fibroblasts, and other stromal cells, making it difficult to dissect the molecular and cellular mechanisms of prolactin cells in pituitary tumorigenesis through high-throughout-omics analysis.
  • Thus, prolactin cell specific molecular events involved in pituitary tumorigenesis and cell signaling can be approached by proteomic analysis.
  • All MS/MS spectrums were analyzed by SEQUEST against the human International Protein Index database and a specific prolactinoma proteome consisting of 2243 proteins was identified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Colloids Surf B Biointerfaces. 2009 Jul 1;71(2):187-93 [19286358.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1205-12 [12429800.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):61-6 [9916919.001]
  • [Cites] Cell. 1996 May 31;85(5):707-20 [8646779.001]
  • [Cites] Neurochem Res. 2003 Aug;28(8):1265-73 [12834267.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • [Cites] Neurosurgery. 1996 Apr;38(4):765-70; discussion 770-1 [8692397.001]
  • [Cites] Front Horm Res. 2004;32:146-74 [15281345.001]
  • [Cites] Nat Protoc. 2006;1(2):586-603 [17406286.001]
  • [Cites] Endocrinology. 2001 May;142(5):1703-9 [11316732.001]
  • [Cites] Electrophoresis. 1995 Jun;16(6):1034-59 [7498127.001]
  • [Cites] J Histochem Cytochem. 2001 Sep;49(9):1193-4 [11511691.001]
  • [Cites] J Chromatogr A. 2006 Nov 24;1135(1):43-51 [17027011.001]
  • [Cites] Electrophoresis. 2008 Jun;29(12):2689-95 [18481836.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1104-15 [10786884.001]
  • [Cites] Mol Cell Proteomics. 2002 Aug;1(8):553-60 [12376570.001]
  • [Cites] Proteome Sci. 2009;7:32 [19719850.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):99-106; discussion 106-7 [8747957.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10296-301 [15240878.001]
  • [Cites] Chem Rev. 2007 Aug;107(8):3654-86 [17649983.001]
  • [Cites] Cancer. 2004 Aug 1;101(3):613-9 [15274075.001]
  • [Cites] Dev Cell. 2002 May;2(5):518-9 [12015958.001]
  • [Cites] Science. 1996 Nov 8;274(5289):998-1001 [8875945.001]
  • [Cites] Electrophoresis. 2003 Jan;24(1-2):296-302 [12652601.001]
  • [Cites] J Cell Sci. 2004 Apr 15;117(Pt 10):1875-84 [15090593.001]
  • [Cites] Int J Clin Exp Pathol. 2008;1(6):475-88 [18787684.001]
  • [Cites] Nature. 2008 Oct 30;455(7217):1251-4 [18820680.001]
  • [Cites] Nat Biotechnol. 1998 Aug;16(8):737-42 [9702771.001]
  • [Cites] Proteome Sci. 2008 Mar 17;6:11 [18346272.001]
  • [Cites] Clin Endocrinol (Oxf). 2000 Sep;53(3):337-44 [10971451.001]
  • [Cites] Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 Jul;34(7):569-75 [19648665.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Mass Spectrom Rev. 2005 Nov-Dec;24(6):783-813 [15495141.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 17;300(3):679-85 [12507503.001]
  • [Cites] Proteomics. 2002 Jan;2(1):3-10 [11788986.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 2003 Jul;49(5):689-712 [14528906.001]
  • [Cites] Pituitary. 2003;6(4):189-202 [15237930.001]
  • [Cites] Oncogene. 2001 May 31;20(25):3290-300 [11423978.001]
  • [Cites] J Chromatogr A. 2004 Jun 4;1038(1-2):247-65 [15233540.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jun;87(6):2635-43 [12050228.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10214-22 [16288009.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):815-22 [11891180.001]
  • [Cites] J Neuroendocrinol. 2007 Nov;19(11):913-22 [17927670.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):604-12 [15253443.001]
  • [Cites] Endocrine. 2005 Oct;28(1):43-7 [16311409.001]
  • [Cites] Nature. 1992 Sep 24;359(6393):295-300 [1406933.001]
  • [Cites] Proteomics. 2003 May;3(5):699-713 [12748949.001]
  • [Cites] Anal Chem. 2008 Sep 1;80(17):6715-23 [18680313.001]
  • [Cites] J Mol Endocrinol. 2009 Feb;42(2):75-86 [18987159.001]
  • [Cites] Eur J Endocrinol. 2000 Jul;143(1):R1-6 [10870044.001]
  • [Cites] Methods Mol Biol. 2008;428:159-78 [18287773.001]
  • [Cites] Proteome Sci. 2008;6:6 [18234112.001]
  • [Cites] Am J Pathol. 1999 Feb;154(2):313-23 [10027389.001]
  • [Cites] Pituitary. 2008;11(3):231-45 [18183490.001]
  • (PMID = 20205839.001).
  • [ISSN] 1477-5956
  • [Journal-full-title] Proteome science
  • [ISO-abbreviation] Proteome Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2825229
  •  go-up   go-down


71. Jensen RL, Jensen PR, Shrieve AF, Hazard L, Shrieve DC: Overall and progression-free survival and visual and endocrine outcomes for patients with parasellar lesions treated with intensity-modulated stereotactic radiosurgery. J Neurooncol; 2010 Jun;98(2):221-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Six patients with cavernous sinus meningiomas and eight with recurrent pituitary adenomas were treated.
  • Three of the pituitary tumors were hormonally active (two with Cushing disease, one with acromegaly).
  • [MeSH-major] Disease-Free Survival. Endocrine System Diseases / etiology. Meningeal Neoplasms / surgery. Pituitary Neoplasms / surgery. Radiosurgery / adverse effects. Vision Disorders / etiology

  • MedlinePlus Health Information. consumer health - Endocrine Diseases.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Vision Impairment and Blindness.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurg Clin N Am. 2000 Oct;11(4):575-86 [11082168.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A19-25 [19165069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jul 15;47(5):1337-45 [10889388.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Oct 1;57(2):580-92 [12957272.001]
  • [Cites] Prog Neurol Surg. 2009;22:77-95 [18948721.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):607-14 [1907958.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Strahlenther Onkol. 2005 May;181(5):336-44 [15900431.001]
  • [Cites] J Neurooncol. 2009 May;92(3):345-56 [19357961.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1481-91 [11286857.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):43-50 [9420071.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1313-9 [11728692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Jul 15;74(4):1018-26 [19217219.001]
  • [Cites] Radiology. 1976 Jul;120(1):167-71 [935443.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jan 1;55(1):99-109 [12504041.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):437-44 [9308948.001]
  • [Cites] Stereotact Funct Neurosurg. 2008;86(5):292-6 [18758206.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Med Dosim. 2003 Summer;28(2):85-90 [12804705.001]
  • [Cites] Important Adv Oncol. 1995;:141-56 [7672802.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1265-70 [12128128.001]
  • [Cites] Neurosurg Clin N Am. 2006 Apr;17(2):67-78, v [16793500.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2009 Jun;21(5):408-16 [19268555.001]
  • [Cites] J Med Assoc Thai. 2009 Mar;92(3):382-9 [19301733.001]
  • [Cites] Rev Endocr Metab Disord. 2009 Jun;10(2):135-44 [18787957.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):446-53; discussion 453-4 [9526976.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A2-9; discussion A9-10 [18580777.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):987-91 [12095567.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):215-21 [8407394.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1177-81 [12654424.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):755-63 [7960976.001]
  • [Cites] J Neurosurg. 2000 Dec;93 Suppl 3:219-22 [11143252.001]
  • [Cites] Otolaryngol Clin North Am. 2009 Aug;42(4):601-21 [19751867.001]
  • [Cites] Med Dosim. 2001 Summer;26(2):143-50 [11444516.001]
  • (PMID = 20461446.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Minniti G, Osti M, Jaffrain-Rea ML, Esposito V, Cantore G, Maurizi Enrici R: Long-term follow-up results of postoperative radiation therapy for Cushing's disease. J Neurooncol; 2007 Aug;84(1):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Radiotherapy is currently used in patients with residual or recurrent pituitary adenomas after surgery.
  • CONCLUSION: Radiotherapy is effective in the long-term tumour- and hormone hypersecretion control of ACTH-secreting pituitary adenomas, however with a high prevalence of hypopituitarism.
  • [MeSH-major] ACTH-Secreting Pituitary Adenoma / radiotherapy. Adenoma / radiotherapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm, Residual / radiotherapy. Pituitary ACTH Hypersecretion / radiotherapy

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Endocrinol (Oxf). 2005 Feb;62(2):210-6 [15670198.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Jan;83(1):63-7 [9435417.001]
  • [Cites] N Engl J Med. 1997 Jan 16;336(3):172-7 [8988897.001]
  • [Cites] Neurosurgery. 2001 Aug;49(2):284-91; discussion 291-2 [11504104.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Oct;85(10):3779-85 [11061538.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):135-40 [11083077.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):57-61; discussion 61-2 [12182435.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Oct 15;30(3):557-65 [7928486.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6348-57 [15579802.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Sep;75(3):935-42 [1517389.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Oct;33(4):445-55 [2225489.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Nov;87(11):4892-9 [12414846.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602 [14671138.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Dec;57(6):713-7 [12460319.001]
  • [Cites] Ann Intern Med. 1988 Sep 15;109(6):487-93 [2843068.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1031-4 [9169809.001]
  • [Cites] J Neurosurg. 2000 Nov;93(5):738-42 [11059652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Sep 30;33(2):307-14 [7673017.001]
  • [Cites] Clin Endocrinol (Oxf). 1993 Jun;38(6):571-8 [8334743.001]
  • [Cites] Acta Endocrinol (Copenh). 1986 Jul;112(3):310-4 [3529780.001]
  • [Cites] N Engl J Med. 1995 Mar 23;332(12):791-803 [7862184.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Nov;61(5):531-43 [15521954.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):422-8 [12507068.001]
  • [Cites] J Neurooncol. 2000 Mar;47(1):79-84 [10930104.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Nov;80(11):3114-20 [7593411.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):34-7 [12519825.001]
  • [Cites] Clin Endocrinol (Oxf). 1985 Feb;22(2):169-77 [3921294.001]
  • [Cites] Clin Endocrinol (Oxf). 1989 Sep;31(3):309-23 [2559823.001]
  • (PMID = 17356896.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


73. Shono T, Mizoguchi M, Yoshimoto K, Amano T, Natori Y, Sasaki T: Clinical course of abducens nerve palsy associated with skull base tumours. Acta Neurochir (Wien); 2009 Jul;151(7):733-8; discussion 738
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The conditions included two pituitary adenomas, two trigeminal schwannomas and five meningiomas.
  • In the four patients with pituitary adenomas and trigeminal schwannomas, all nerves were anatomically preserved and showed complete recovery of function within 6 months after surgery.
  • CONCLUSIONS: The abducens nerve palsies in pituitary adenomas and trigeminal schwannomas showed a better clinical course compared to those in skull base meningiomas.
  • [MeSH-major] Abducens Nerve / surgery. Abducens Nerve Diseases / etiology. Abducens Nerve Diseases / surgery. Skull Base Neoplasms / complications. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adenoma / complications. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cranial Fossa, Posterior / pathology. Cranial Fossa, Posterior / surgery. Cranial Nerve Neoplasms / complications. Cranial Nerve Neoplasms / pathology. Cranial Nerve Neoplasms / surgery. Female. Fibrin Tissue Adhesive / therapeutic use. Humans. Male. Meningeal Neoplasms / complications. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / complications. Meningioma / pathology. Meningioma / surgery. Middle Aged. Neurilemmoma / complications. Neurilemmoma / pathology. Neurilemmoma / surgery. Neurosurgical Procedures / adverse effects. Neurosurgical Procedures / methods. Pituitary Neoplasms / complications. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Prognosis. Reconstructive Surgical Procedures / methods. Recovery of Function / physiology. Retrospective Studies. Treatment Outcome. Trigeminal Nerve Diseases / complications. Trigeminal Nerve Diseases / pathology. Trigeminal Nerve Diseases / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387538.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Fibrin Tissue Adhesive
  •  go-up   go-down


74. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA: The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol; 2009 Dec;95(3):401-411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported.
  • The most common histology was meningioma (n = 504, 29.9%) followed by glioblastoma (n = 340, 20.1%) and pituitary adenoma (n = 151, 8.9%).
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Austria / epidemiology. Child. Child, Preschool. Ependymoma / epidemiology. Ependymoma / pathology. Female. Geographic Information Systems. Humans. Incidence. Male. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / pathology. Middle Aged. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Reproducibility of Results. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] J Neurooncol. 1999 May;42(3):195-204 [10433103.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):348-57 [10637249.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):842-8 [16136046.001]
  • [Cites] Epidemiology. 2004 Nov;15(6):653-9 [15475713.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4104-9 [17827460.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):925-46, viii [17964021.001]
  • [Cites] AIDS Read. 2000 Aug;10(8):486-91 [10967810.001]
  • [Cites] Dis Nerv Syst. 1967 Feb;28(2):89-93 [5336568.001]
  • [Cites] Neurosurgery. 1987 Jul;21(1):21-6 [3039398.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] Neurosurg Focus. 2005 Apr 15;18(4):e12 [15844864.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Epidemiol Biostat. 2000;5(2):99-107 [10890281.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):189-99 [17431547.001]
  • [Cites] J Neurooncol. 1994;18(1):69-81 [8057137.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] Int J Oncol. 2008 May;32(5):1097-103 [18425337.001]
  • [Cites] Surg Neurol. 2006 Sep;66(3):258-63; discussion 263 [16935629.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):484-9 [18349266.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Neuroepidemiology. 2006;27(1):22-7 [16770081.001]
  • [Cites] Int J Clin Oncol. 2008 Apr;13(2):90-6 [18463950.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • (PMID = 19562257.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, van Aken MO, Voormolen JH, Romijn JA: Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab; 2007 Mar;92(3):976-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma.
  • CONTEXT: Increased mortality in patients with pituitary tumors after surgical treatment has been reported.
  • However, it is unknown to what extent excess mortality is caused by pituitary tumors and their treatment in general and to what extent by previous exposure to hormonal overproduction.
  • OBJECTIVE: The aim of the study was to compare mortality between patients treated for Cushing's disease and nonfunctioning pituitary macroadenomas (NFMAs).
  • PATIENTS: We included 248 consecutive patients with pituitary adenomas treated by transsphenoidal surgery in our hospital for NFMAs (n = 174) and ACTH-producing adenomas (n = 74).
  • OUTCOME MEASURES: The standardized mortality ratio (SMR) was calculated for the whole cohort and also for the two diseases separately.
  • [MeSH-major] Adenoma / mortality. Pituitary ACTH Hypersecretion / mortality. Pituitary Neoplasms / mortality

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200171.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Cozzi L, Clivio A, Bauman G, Cora S, Nicolini G, Pellegrini R, Vanetti E, Yartsev S, Fogliata A: Comparison of advanced irradiation techniques with photons for benign intracranial tumours. Radiother Oncol; 2006 Aug;80(2):268-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of advanced irradiation techniques with photons for benign intracranial tumours.
  • BACKGROUND AND PURPOSE: The potential benefits and limitations of different radiation techniques (stereotactic arc therapy (SRS/T), intensity modulated radiotherapy (IMRT), helical tomotherapy (HT), Cyberknife and intensity-modulated multiple arc therapy (AMOA)) have been assessed using comparative treatment planning methods on twelve patients presenting with 'benign' brain tumours.
  • MATERIALS AND METHODS: Plans for five acoustic neurinomas, five meningiomas and two pituitary adenomas were computed to generate dose distributions for all modalities using a common CT dataset to delineate planning target volume and organs at risk.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16890315.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


77. Caron P: [Thyrotropin-secreting pituitary adenomas]. Presse Med; 2009 Jan;38(1):107-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thyrotropin-secreting pituitary adenomas].
  • TSH-secreting pituitary adenomas represent 0.5 to 1% of all pituitary adenomas.
  • They are recognized with increasing frequency due to the measurement of TSH level in patients with hyperthyroidism, the ultra sensitive TSH assays and the improvement in pituitary imaging.
  • Hormonal evaluation shows increased free thyroid hormone concentration with detectable, normal or increased serum TSH level, raising the differential diagnosis with pituitary resistance to thyroid hormone syndrome.
  • Magnetic resonance imaging reveals pituitary adenomas in most patients.
  • Transphenoidal surgery remains the treatment of choice in patients with TSH-secreting pituitary microadenomas, while long-acting somatostatin analogs seem to be an alternative medical treatment to surgery in patients with macroadenomas or invasive pituitary tumors.
  • [MeSH-major] Adenoma / diagnosis. Pituitary Neoplasms / diagnosis. Thyrotropin / secretion
  • [MeSH-minor] Diagnosis, Differential. Humans. Hyperthyroidism / diagnosis. Magnetic Resonance Imaging. Neoadjuvant Therapy. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use. Thyroxine / blood

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18980829.001).
  • [ISSN] 2213-0276
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 51110-01-1 / Somatostatin; 9002-71-5 / Thyrotropin; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


78. Orrego JJ, Bair J: Development of a macroprolactinoma in association with hormone replacement therapy in a perimenopausal woman with presumed idiopathic hyperprolactinemia. Endocr Pract; 2006 Mar-Apr;12(2):174-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The only clue for ordering a pituitary imaging study in this case was a substantial increase in the level of the serum prolactin.
  • Treatment with cabergoline normalized the patient's serum prolactin level and considerably decreased the size of her pituitary adenoma.
  • [MeSH-major] Estrogen Replacement Therapy / adverse effects. Hyperprolactinemia / complications. Pituitary Neoplasms / etiology. Prolactinoma / etiology

  • Genetic Alliance. consumer health - Galactorrhoea-Hyperprolactinaemia.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690466.001).
  • [ISSN] 1530-891X
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports
  • [Publication-country] United States
  • [Chemical-registry-number] 9002-62-4 / Prolactin; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


79. Berkmann S, Tolnay M, Hänggi D, Ghaffari A, Gratzl O: Sarcoma of the sella after radiotherapy for pituitary adenoma. Acta Neurochir (Wien); 2010 Oct;152(10):1725-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma of the sella after radiotherapy for pituitary adenoma.
  • Secondary malignancies are infrequent sequelae of pituitary radiotherapy.
  • Radiation-induced sarcoma is a rare sequela of pituitary radiotherapy.
  • Additionally, one must include these tumors into the differential diagnosis in pituitary patients presenting with tumor recurrence more than 5 years after radiotherapy in combination with a secondary lack of hormonal activity.
  • [MeSH-major] Adenoma / radiotherapy. Fibrosarcoma / etiology. Fibrosarcoma / pathology. Pituitary Neoplasms / radiotherapy. Radiotherapy / adverse effects. Skull Base Neoplasms / etiology. Skull Base Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20512596.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


80. Fraioli MF, Moschettoni L, Fraioli C: Pituitary adenomas. J Neurosurg; 2008 Aug;109(2):362-3; author reply 363-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pituitary adenomas.
  • [MeSH-major] Adenoma / pathology. Adenoma / surgery. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Neurosurg. 2008 Jan;108(1):26-36 [18173307.001]
  • (PMID = 18671656.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


81. Kowarik M, Onofri C, Colaco T, Stalla GK, Renner U: Platelet-derived growth factor (PDGF) and PDGF receptor expression and function in folliculostellate pituitary cells. Exp Clin Endocrinol Diabetes; 2010 Feb;118(2):113-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor (PDGF) and PDGF receptor expression and function in folliculostellate pituitary cells.
  • Since little information is available on the impact of PDGF/PDGF receptors in normal and adenomatous pituitary, we studied the expression and action of this growth factor system in a variety of pituitary tumour cell lines and in rat anterior pituitary cell cultures.
  • By RT-PCR, mRNA expression of PDGF-A and -B chains and of both receptors was found in rat pituitary and mouse folliculostellate TtT/GF pituitary tumour cells.
  • Rat somatotroph MtT-S and mouse corticotroph AtT20 tumor cells expressed only a part of the PDGF/PDGF receptor components whereas mouse gonadotroph alphaT3-1 and rat lactosomatotroph GH3 pituitary tumour cells contained neither PDGF nor PDGF receptors.
  • Both in rat pituitary cell cultures and in TtT/GF cells, PDGF-AB and -BB strongly enhanced VEGF-A secretion.
  • Its role in endocrine pituitary tumour cell lines and pituitary adenomas need to be clarified in future studies.
  • [MeSH-major] Pituitary Gland, Anterior / metabolism. Platelet-Derived Growth Factor / metabolism. Receptors, Platelet-Derived Growth Factor / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart. New York.
  • (PMID = 19373754.001).
  • [ISSN] 1439-3646
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptors, Platelet-Derived Growth Factor
  •  go-up   go-down


82. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC: Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer; 2007 Mar;14(1):91-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
  • Somatostatin (SRIF) analogs have been employed in medical therapy of non-functioning pituitary adenomas (NFA), with contrasting results.
  • Previous evidence showed that SRIF can exert its antiproliferative effects by reducing vascular endothelial growth factor (VEGF) secretion and action, and that VEGF expression may be related to pituitary tumor growth.
  • [MeSH-major] Adenoma / secretion. Oligopeptides / pharmacology. Pituitary Neoplasms / secretion. Somatostatin / pharmacology. Vascular Endothelial Growth Factor A / secretion

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17395978.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Hormones; 0 / Ligands; 0 / Oligopeptides; 0 / RNA, Messenger; 0 / Receptors, Somatostatin; 0 / Vascular Endothelial Growth Factor A; 51110-01-1 / Somatostatin; 98H1T17066 / pasireotide
  •  go-up   go-down


83. Garnett MR, Puget S, Grill J, Sainte-Rose C: Craniopharyngioma. Orphanet J Rare Dis; 2007;2:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are benign slow growing tumours that are located within the sellar and para sellar region of the central nervous system.
  • The onset of symptoms is normally insidious with most patients at diagnosis having neurological (headaches, visual disturbances) and endocrine (growth retardation, delayed puberty) dysfunctions.
  • The neuroradiological diagnosis is mainly based on the three components of the tumour (cystic, solid and calcified) in the characteristic sellar/para sellar location.
  • Definitive diagnosis is made following histological examination of a surgical specimen.
  • The differential diagnosis includes other tumours in this region (pituitary adenoma), infectious or inflammatory processes (eosinophilic granuloma), vascular malformations (aneurysm) and congenital anomalies (Rathke's cleft cyst).
  • [MeSH-major] Craniopharyngioma / diagnosis. Craniopharyngioma / therapy. Pituitary Neoplasms / diagnosis. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adult. Child. Diagnosis, Differential. Humans. Medical Oncology / methods. Prognosis. Quality of Life

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):764-9 [10603020.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):255-63 [10760417.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):4769-75 [16968795.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1053-7; discussion 1057-8 [11846897.001]
  • [Cites] Acta Neurochir (Wien). 2002 Apr;144(4):403-4 [12021891.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):533-42 [12062594.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):1-2; discussion 2 [12134898.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1):3-11 [12134929.001]
  • [Cites] Dev Med Child Neurol. 2004 Apr;46(4):220-9 [15077699.001]
  • [Cites] J Neurosurg. 1970 Dec;33(6):689-707 [5488801.001]
  • [Cites] Neurosurgery. 1982 Jul;11(1 Pt 1):12-5 [6287341.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):409-17 [6886754.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1984 Oct;47(10):1075-80 [6502164.001]
  • [Cites] Neurochirurgie. 1984;30(5):347-9 [6521815.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:350-8 [3628817.001]
  • [Cites] Childs Nerv Syst. 1988 Apr;4(2):97-9 [3401877.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):3-11 [2352020.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):534-40 [2398383.001]
  • [Cites] Neurology. 1991 May;41(5):726-9 [2027490.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):1025-6 [2033440.001]
  • [Cites] Neurol Clin. 1991 May;9(2):453-65 [1944109.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):47-52 [1727168.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:11-7 [7841069.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Jul;81(7):2734-7 [8675604.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):73-81 [8683285.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Mar;22(2):89-101 [15804994.001]
  • [Cites] Neurosurg Focus. 2005 Jun 15;18(6A):E6 [16048292.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):729-46 [16044343.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):808-16 [16075214.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):691-5 [16078079.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):719-24 [16133276.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:289-93 [16700303.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:299-319 [16700305.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:325-7 [16700307.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:329-35 [16700308.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:337-40 [16700309.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:389-94 [16700315.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:407-12 [16700318.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • (PMID = 17425791.001).
  • [ISSN] 1750-1172
  • [Journal-full-title] Orphanet journal of rare diseases
  • [ISO-abbreviation] Orphanet J Rare Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 43
  • [Other-IDs] NLM/ PMC1855047
  •  go-up   go-down


84. La Rosa S, Vigetti D, Placidi C, Finzi G, Uccella S, Clerici M, Bartolini B, Carnevali I, Losa M, Capella C: Localization of carboxyl ester lipase in human pituitary gland and pituitary adenomas. J Histochem Cytochem; 2010 Oct;58(10):881-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of carboxyl ester lipase in human pituitary gland and pituitary adenomas.
  • Carboxyl ester lipase (CEL) is an enzyme that hydrolyzes a wide variety of lipid substrates, including ceramides, which are known to show inhibitory regulation of pituitary hormone secretion in experimental models.
  • Because no studies on CEL expression in human pituitary and pituitary adenomas have been reported in the literature, we investigated CEL expression in 10 normal pituitary glands and 86 well-characterized pituitary adenomas [12 FSH/LH cell, 17 α-subunit/null cell, 6 TSH cell, 21 ACTH cell, 11 prolactin (PRL) cell, and 19 GH cell adenomas] using IHC, immunoelectron microscopy, Western blotting, and quantitative RT-PCR.
  • In adenomas, it was mainly found in functioning GH, ACTH, and TSH tumors, whereas its expression was poor in the corresponding silent adenomas and was lacking in FSH/LH cell, null cell, and PRL cell adenomas.
  • This is the first study demonstrating CEL expression in normal human pituitary glands and in functioning GH, ACTH, and TSH adenomas.
  • Considering that CEL hydrolyzes ceramides, inactivating their inhibitory function on pituitary hormone secretion, our findings suggest a possible role of CEL in the regulation of hormone secretion in both normal and adenomatous pituitary cells.
  • [MeSH-major] Adenoma / enzymology. Lipase / biosynthesis. Pituitary Gland / enzymology. Pituitary Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 1999 Dec;140(12):5691-7 [10579333.001]
  • [Cites] Virchows Arch. 2009 Dec;455(6):527-31 [19908063.001]
  • [Cites] Endocrinology. 2001 Nov;142(11):4785-94 [11606445.001]
  • [Cites] J Biol Chem. 2002 Feb 8;277(6):4104-9 [11733511.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48427-33 [12376552.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 15;218(1-2):175-83 [15130522.001]
  • [Cites] Biochim Biophys Acta. 1978 Nov 10;527(1):142-9 [718955.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Sep 15;155(2):950-5 [3421974.001]
  • [Cites] J Clin Invest. 1990 Apr;85(4):1221-6 [2318975.001]
  • [Cites] Eur J Biochem. 1990 Sep 11;192(2):543-50 [1698625.001]
  • [Cites] FEBS Lett. 1991 Jan 28;278(2):190-4 [1991511.001]
  • [Cites] Differentiation. 1992 Sep;51(1):55-60 [1451962.001]
  • [Cites] J Biol Chem. 1993 Mar 5;268(7):4577-9 [8383117.001]
  • [Cites] Biochem J. 1993 Apr 1;291 ( Pt 1):65-9 [8471055.001]
  • [Cites] J Biol Chem. 1994 Feb 4;269(5):3125-8 [8106344.001]
  • [Cites] J Histochem Cytochem. 1995 Jan;43(1):97-102 [7822770.001]
  • [Cites] Biochim Biophys Acta. 1995 Oct 17;1272(2):69-72 [7548236.001]
  • [Cites] Biochem J. 1998 Feb 1;329 ( Pt 3):675-9 [9445398.001]
  • [Cites] Biochem J. 1998 Nov 1;335 ( Pt 3):465-80 [9794783.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38592-8 [16166077.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4448-58 [18077444.001]
  • [Cites] Histochem Cell Biol. 2008 Aug;130(2):299-313 [18553098.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1483-94 [18619649.001]
  • [Cites] Virchows Arch. 2009 Feb;454(2):133-42 [19066953.001]
  • [Cites] J Cell Sci. 2000 Sep;113 ( Pt 18):3299-307 [10954427.001]
  • (PMID = 20566755.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.1.3 / CEL protein, human; EC 3.1.1.3 / Lipase
  • [Other-IDs] NLM/ PMC2942741
  •  go-up   go-down


85. Zhang Y, Wang Z, Liu Y, Zong X, Song M, Pei A, Zhao P, Zhang P, Piao M: Endoscopic transsphenoidal treatment of pituitary adenomas. Neurol Res; 2008 Jul;30(6):581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic transsphenoidal treatment of pituitary adenomas.
  • OBJECTIVE: To explore the techniques and methods of endoscopic transnasal transsphenoid surgery for pituitary adenoma.
  • METHOD: We treated 678 cases with pituitary adenoma by endoscopic transsphenoidal surgery between May 2000 and May 2006.
  • RESULTS: Among the 678 pituitary adenomas, tumor removal was total in 543 (80.1%), subtotal in 118 (17.4%) and partial in 17 (2.5%).
  • CONCLUSION: Endoscopic transsphenoidal surgery of pituitary adenomas is a valuable microinvasive neurosurgery technique of minimal invasiveness, being effective and safe, yet requiring simple manipulation.
  • [MeSH-major] Adenoma / surgery. Hypophysectomy / methods. Neuroendoscopy / methods. Pituitary Neoplasms / surgery. Sphenoid Sinus / surgery

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18647497.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Mondok A, Tóth M, Patócs A, Szücs N, Igaz P, Pusztai P, Czirják S, Beko G, Gláz E, Rácz K, Tulassay Z: [Outcome of somatostatin analogue treatment in acromegaly]. Orv Hetil; 2009 Aug 2;150(31):1457-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Changes in serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) concentration, as well as morphologic changes of pituitary adenomas followed by MRI scans were evaluated and compared in 32 acromegalic patients (26 women, 6 men) during long-term somatostatin analogue treatment (mean+/-SE, 3.1+/-0.3 years, range, 1-7 years).
  • Primary somatostatin analogue treatment was applied in 10 patients (7 women and 3 men), whereas 15 patients (14 women and 1 man) had pituitary surgery and 7 patients (5 women and 2 men) underwent both pituitary surgery and irradiation therapy prior to somatostatin analogue treatment.
  • Pituitary MRI showed regression of the adenoma in 46% of patients, and none of the patients had progression of the pituitary adenoma.
  • CONCLUSIONS: Somatostatin analogues are effective therapeutic options for acromegalic patients when primary surgical treatment cannot be performed due to complications and associated disorders, or in patients whose acromegaly remains active after pituitary surgery or after pituitary surgery and irradiation.
  • [MeSH-major] Acromegaly / drug therapy. Acromegaly / etiology. Adenoma / complications. Adenoma / therapy. Pituitary Neoplasms / complications. Pituitary Neoplasms / therapy. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use

  • Genetic Alliance. consumer health - Acromegaly.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617182.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 12629-01-5 / Human Growth Hormone; 51110-01-1 / Somatostatin; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


87. Arita K, Tominaga A, Sugiyama K, Eguchi K, Iida K, Sumida M, Migita K, Kurisu K: Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination. J Neurosurg; 2006 Jun;104(6):884-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural course of incidentally found nonfunctioning pituitary adenoma, with special reference to pituitary apoplexy during follow-up examination.
  • OBJECT: The increase in the incidental detection of asymptomatic pituitary adenomas, known as "pituitary incidentalomas," led the authors to conduct a survey of the natural course of these lesions.
  • METHODS: Forty-two patients with clinically nonfunctioning pituitary adenomas who had manifested no neurological or endocrinological disorders were monitored with magnetic resonance imaging studies.
  • This increase was first detected between 8.4 and 58.8 months (mean 31.8 +/- 17.6 months) after diagnosis.
  • Symptoms were noted in 10 patients during follow up; in four, extensive tumor necrosis accompanied hemorrhage, leading to severe headache, acute ophthalmological symptoms, and panhypopituitarism, which was indicative of pituitary apoplexy.
  • During the 5-year follow up, pituitary apoplexy developed in 9.5%.
  • [MeSH-major] Adenoma / pathology. Pituitary Apoplexy / epidemiology. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16776331.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Hossain MG, Iwata T, Mizusawa N, Qian ZR, Shima SW, Okutsu T, Yamada S, Sano T, Yoshimoto K: Expression of p18(INK4C) is down-regulated in human pituitary adenomas. Endocr Pathol; 2009;20(2):114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p18(INK4C) is down-regulated in human pituitary adenomas.
  • Mice lacking p18(Ink4c) exhibit a series of phenotypes including the development of widespread organomegaly and pituitary adenomas.
  • The objective of our study is to examine the role of p18(INK4C) in the pathogenesis of human pituitary tumors.
  • The methylation status of the p18(INK4C) gene promoter and somatic mutations of the p18(INK4C) gene were also investigated. p18(INK4C) protein expression was lost or significantly reduced in 64% of pituitary adenomas compared with levels in normal pituitary glands. p18(INK4C) mRNA levels were low in all ACTH adenomas and non-functioning (NF)-FSH and in 42%, 70% and 66% of GH, PRL, and subtype 3 adenomas, respectively. p18(INK4C) mRNA levels were significantly associated with p18(INK4C) protein levels.
  • Neither methylated promoters in pituitary adenomas, except in one NF-FSH adenoma, nor somatic mutations of the p18(INK4C) gene in any pituitary adenomas were detected.
  • The down-regulation of p18(INK4C) expression may contribute to the tumorigenesis of pituitary adenomas.
  • [MeSH-major] Adenoma / genetics. Cyclin-Dependent Kinase Inhibitor p18 / genetics. Cyclin-Dependent Kinase Inhibitor p18 / metabolism. Gene Expression Regulation, Neoplastic. Pituitary Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocr J. 1999 Feb;46(1):199-207 [10426588.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2493-6 [8653683.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87 [11960696.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):554-70 [16953232.001]
  • [Cites] J Mol Biol. 2007 Jun 1;369(2):313-21 [17442339.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2564-9 [18381405.001]
  • [Cites] Cancer Res. 1992 Sep 15;52(18):5061-4 [1516062.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Blood. 2004 Mar 15;103(6):2351-7 [14645011.001]
  • [Cites] J Clin Oncol. 2006 Apr 10;24(11):1770-83 [16603719.001]
  • [Cites] Jpn J Cancer Res. 1992 Oct;83(10):1057-62 [1452458.001]
  • [Cites] J Bone Miner Res. 1997 Sep;12(9):1330-4 [9286748.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):31679-93 [12077144.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):285-95 [15057288.001]
  • [Cites] J Neurooncol. 2007 Jun;83(2):153-62 [17216555.001]
  • [Cites] Cancer Lett. 2007 Jun 28;251(2):187-98 [17166656.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Apr;58(4):464-70 [12641630.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Aug;83(8):2631-4 [9709923.001]
  • [Cites] Hepatology. 2004 Sep;40(3):677-86 [15349907.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14659-64 [16195383.001]
  • [Cites] Neoplasia. 2007 Jul;9(7):533-5 [17710155.001]
  • [Cites] Genes Dev. 1998 Sep 15;12(18):2899-911 [9744866.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Eur J Endocrinol. 2005 Jul;153(1):143-51 [15994756.001]
  • [Cites] Mol Cell Biol. 2006 Jun;26(12 ):4564-76 [16738322.001]
  • [Cites] Genes Dev. 2005 Nov 15;19(22):2656-67 [16260494.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1329-37 [18316595.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):836-49 [12415254.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1891-6 [17244780.001]
  • [Cites] Mol Cell Biol. 2007 Feb;27(4):1495-504 [17145768.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):370-5 [10652429.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Feb;48(2):143-54 [18973139.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Apr;89(4):1904-11 [15070963.001]
  • [Cites] Clin Endocrinol (Oxf). 2007 Apr;66(4):499-502 [17371465.001]
  • [Cites] Endocr J. 2003 Jun;50(3):309-18 [12940460.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Feb;86(2):136-42 [8603340.001]
  • (PMID = 19401813.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p18; 0 / RNA, Messenger
  •  go-up   go-down


89. Ma L, Li G, Su Y, He Q, Zhang C, Zhang J: The soluble major histocompatibility complex class I-related chain A protein reduced NKG2D expression on natural killer and T cells from patients with prolactinoma and non-secreting pituitary adenoma. J Clin Neurosci; 2010 Feb;17(2):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The soluble major histocompatibility complex class I-related chain A protein reduced NKG2D expression on natural killer and T cells from patients with prolactinoma and non-secreting pituitary adenoma.
  • This study analyses aspects of the immune system in prolactinoma and non-secreting pituitary adenoma.
  • We found decreased percentage and mean fluorescence intensity of NKG2D-expressing natural killer and T cells from patients with prolactinoma and non-secreting pituitary adenoma compared to those from healthy donors.
  • The immune-escape of pituitary adenoma is related to the down-regulation of NKG2D and the up-regulation of its ligand MICA.
  • [MeSH-major] Histocompatibility Antigens Class I / blood. Killer Cells, Natural / metabolism. NK Cell Lectin-Like Receptor Subfamily K / metabolism. Pituitary Neoplasms / blood. Prolactinoma / blood. T-Lymphocytes / metabolism. Tumor Escape / physiology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Crown Copyright 2009. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20045334.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Histocompatibility Antigens Class I; 0 / KLRK1 protein, human; 0 / MHC class I-related chain A; 0 / NK Cell Lectin-Like Receptor Subfamily K
  •  go-up   go-down


90. Tiemensma J, Biermasz NR, van der Mast RC, Wassenaar MJ, Middelkoop HA, Pereira AM, Romijn JA: Increased psychopathology and maladaptive personality traits, but normal cognitive functioning, in patients after long-term cure of acromegaly. J Clin Endocrinol Metab; 2010 Dec;95(12):E392-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compared these data with 60 patients treated for nonfunctioning pituitary macroadenomas (NFMAs) and 60 matched controls.
  • These results suggest irreversible effects of previous GH excess, rather than effects of pituitary adenomas per se and/or their treatment, on the central nervous system.
  • [MeSH-major] Acromegaly / psychology. Long-Term Care / psychology. Mental Disorders / etiology. Personality Disorders / etiology. Pituitary Neoplasms / psychology


91. Yasuda M, Akiyama N, Miyamoto S, Warabi M, Takahama Y, Kitamura M, Yakushiji F, Kinoshita H: Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma. Pituitary; 2010;13(1):39-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lymphoma is one of the causative factors of hypothalamus-pituitary dysfunction, and intravascular large B-cell lymphoma (IVLBCL) is a subtype of primary extranodal neoplasm.
  • We diagnosed her with presumable non-functional primary pituitary adenoma and subsequent dysfunction.
  • Though we conducted systemic investigations including chest and abdomen enhanced computer tomography, transbronchial lung biopsy, and bone marrow biopsy, the diagnosis was not confirmed.
  • In affected sites, both sellar and pituitary stalk (6.7%), both hypothalamus and pituitary stalk (6.7%), only sellar (63.3%), only pituitary stalk (6.7%), only hypothalamus (13.3%), and only clivus (3.3%) were observed.
  • In hypothalamus-pituitary dysfunction, both anterior and posterior dysfunction (20.7%), only anterior dysfunction (58.6%), only posterior dysfunction (3.4%), and no dysfunction (17.2%) were observed.
  • It seemed that hypothalamic lesion is related to both anterior and posterior dysfunction, while sellar lesion is related to mainly anterior dysfunction.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Pituitary Neoplasms / diagnosis. Sella Turcica / pathology. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Cranial Nerves / physiology. Cranial Nerves / physiopathology. Female. Humans. Neoplasms, Second Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2007 Sep;107(3):660-5 [17886569.001]
  • [Cites] Acta Neuropathol. 1999 Mar;97(3):311-6 [10090680.001]
  • [Cites] Endocr J. 2005 Oct;52(5):543-9 [16284431.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):112-23 [2420221.001]
  • [Cites] Am J Med. 1999 Aug;107(2):169-76 [10460050.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3168-73 [17577023.001]
  • [Cites] Acta Neurochir (Wien). 2008 Aug;150(8):833-6 [18574548.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Apr;86(4):1470-6 [11297569.001]
  • [Cites] Pituitary. 2011 Jun;14 (2):194-7 [19123039.001]
  • [Cites] Mayo Clin Proc. 2007 Dec;82(12):1525-7 [18053461.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Endocrinol Metab Clin North Am. 1999 Mar;28(1):81-117, vi [10207686.001]
  • [Cites] Australas Radiol. 2000 Feb;44(1):112-4 [10761271.001]
  • [Cites] Am J Clin Pathol. 1979 Jun;71(6):724-7 [377944.001]
  • [Cites] Endocr Pathol. 2009 Spring;20(1):46-9 [19229666.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] Pituitary. 2009;12(1):76-9 [18205050.001]
  • [Cites] Am J Med. 1996 Nov;101(5):563-4 [8948282.001]
  • [Cites] Endocr Pract. 2003 Jul-Aug;9(4):296-300 [14561574.001]
  • [Cites] Wien Klin Wochenschr. 2006 Jul;118(13-14):422-5 [16865648.001]
  • [Cites] Am J Med Sci. 2004 Aug;328(2):124-8 [15311173.001]
  • [Cites] Am J Hematol. 2000 Apr;63(4):231-2 [10706771.001]
  • [Cites] Histopathology. 1997 Aug;31(2):161-6 [9279568.001]
  • [Cites] Pituitary. 2000 May;2(4):283-7 [11081150.001]
  • [Cites] Exp Clin Endocrinol. 1993;101(5):283-9 [8299704.001]
  • [Cites] Endocr Pathol. 1997 Winter;8(4):335-341 [12114795.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):236-44 [18081700.001]
  • [Cites] J R Soc Med. 1997 May;90(5):274-5 [9204025.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 May;23(5):838-40 [12006288.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):236-9 [15224358.001]
  • [Cites] Folia Neuropathol. 2007;45(3):144-8 [17849366.001]
  • [Cites] Rinsho Shinkeigaku. 1999 Nov;39(11):1160-3 [10689943.001]
  • [Cites] Nihon Kokyuki Gakkai Zasshi. 2000 Jan;38(1):34-8 [10723949.001]
  • [Cites] No To Shinkei. 1998 Dec;50(12):1133-41 [9989361.001]
  • [Cites] Indian J Cancer. 1993 Jun;30(2):88-91 [8225384.001]
  • [Cites] N Engl J Med. 1994 Sep 29;331(13):861-8 [8078533.001]
  • [Cites] Dermatology. 2004;209(2):135-7 [15316168.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):130-3 [11216706.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Mar;23(3):364-7 [11901000.001]
  • [Cites] Surg Neurol. 2002 Sep-Oct;58(3-4):246-50 [12480233.001]
  • [Cites] No Shinkei Geka. 1998 Jan;26(1):53-8 [9488992.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1611-6 [15370213.001]
  • [Cites] Medicine (Baltimore). 1999 Jul;78(4):236-69 [10424206.001]
  • [Cites] Med Pediatr Oncol. 2001 Mar;36(3):392-5 [11241445.001]
  • [Cites] Cas Lek Cesk. 2008;147(11):569-73 [19097361.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Cancer. 1994 Mar 15;73(6):1738-45 [8156502.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):227-31 [15072472.001]
  • [Cites] Blood. 2007 Jan 15;109(2):478-85 [16985183.001]
  • [Cites] J Clin Oncol. 2008 Jul 1;26(19):3189-95 [18506023.001]
  • [Cites] Endocrine. 2008 Aug-Dec;34(1-3):11-6 [18937075.001]
  • [Cites] J Clin Neurosci. 2008 Oct;15(10):1148-51 [18653342.001]
  • (PMID = 19707877.001).
  • [ISSN] 1573-7403
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 50
  •  go-up   go-down


92. Lehman NL: The ubiquitin proteasome system in neuropathology. Acta Neuropathol; 2009 Sep;118(3):329-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In neuropathology, alteration of the UPS, or mutations in UPS target proteins may result in signaling abnormalities leading to the initiation or progression of tumors such as astrocytomas, hemangioblastomas, craniopharyngiomas, pituitary adenomas, and medulloblastomas.
  • In neurodegenerative diseases caused by the expression of mutant proteins, the cellular accumulation of these proteins may overload the UPS, indirectly contributing to the disease process, e.g., sporadic Parkinsonism and prion diseases.
  • Defects or dysfunction of the UPS may also underlie cognitive disorders such as Angelman syndrome, Rett syndrome and autism, and muscle and nerve diseases, e.g., inclusion body myopathy and giant axon neuropathy.
  • This paper describes the basic biochemical mechanisms comprising the UPS and reviews both its theoretical and proven involvement in neuropathological diseases.
  • [MeSH-minor] Brain Diseases / metabolism. Brain Neoplasms / metabolism. Humans. Neurodegenerative Diseases / metabolism. Substrate Specificity

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11 [17360485.001]
  • [Cites] Nature. 2009 May 28;459(7246):569-73 [19404257.001]
  • [Cites] Mol Cell. 2007 Apr 27;26(2):175-88 [17466621.001]
  • [Cites] Cell. 1999 Mar 5;96(5):635-44 [10089879.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5416-25 [18765533.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] J Neurosci. 2004 Sep 29;24(39):8410-5 [15456813.001]
  • [Cites] Cell Cycle. 2006 Jul;5(14):1569-73 [16861914.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2820-30 [19369384.001]
  • [Cites] Neuron. 2005 Sep 1;47(5):629-32 [16129392.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1026-30 [14716021.001]
  • [Cites] Curr Top Dev Biol. 2006;76:89-101 [17118264.001]
  • [Cites] J Biol Chem. 2008 Feb 8;283(6):3316-28 [18070888.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25733-41 [10823831.001]
  • [Cites] Ann Neurol. 2007 May;61(5):427-34 [17469116.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3557-60 [17690257.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12876-82 [14709552.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24315-21 [1447181.001]
  • [Cites] Neurochem Int. 2007 Jul-Sep;51(2-4):105-11 [17586089.001]
  • [Cites] Cell Div. 2008 Apr 22;3:8 [18430235.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3940-51 [17992259.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):735-49 [12628165.001]
  • [Cites] Curr Biol. 1999 Feb 25;9(4):207-10 [10074433.001]
  • [Cites] J Neurochem. 2008 Dec;107(6):1471-81 [19094054.001]
  • [Cites] Toxicol Pathol. 2008 Feb;36(2):345-52 [18362199.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8929-35 [10722740.001]
  • [Cites] Cell Signal. 2008 Oct;20(10):1725-39 [18602463.001]
  • [Cites] Acta Neuropathol. 2000 Jul;100(1):43-9 [10912919.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2408-19 [14743209.001]
  • [Cites] J Child Neurol. 2008 Aug;23(8):912-5 [18487518.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21323-6 [12719435.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):74-81 [16616114.001]
  • [Cites] Nat Neurosci. 2009 Jun;12(6):777-83 [19430469.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5484-9 [11729185.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2009;49:73-96 [18834306.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1186-9 [18796596.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):42290-301 [15280365.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8 [17210620.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):695-707 [17050664.001]
  • [Cites] Hum Mol Genet. 2008 Dec 15;17(24):3942-52 [18784277.001]
  • [Cites] PLoS One. 2009;4(3):e4973 [19319192.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] J Cell Sci. 2004 Jan 15;117(Pt 2):281-92 [14657277.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2629-34 [19196987.001]
  • [Cites] Neurobiol Dis. 2005 Dec;20(3):646-55 [15936949.001]
  • [Cites] Trends Cell Biol. 2000 Dec;10(12):524-30 [11121744.001]
  • [Cites] J Cell Biol. 2008 Mar 24;180(6):1177-89 [18362179.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):6002-11 [18574468.001]
  • [Cites] J Neurochem. 2005 Mar;92(6):1531-41 [15748170.001]
  • [Cites] J Mol Biol. 2006 Mar 3;356(4):1027-35 [16405905.001]
  • [Cites] Cell Mol Life Sci. 2007 Mar;64(5):601-9 [17256086.001]
  • [Cites] Acta Neuropathol. 2008 Aug;116(2):159-67 [18553091.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2314-23 [19276349.001]
  • [Cites] Neurology. 2006 Sep 26;67(6):1074-7 [16807408.001]
  • [Cites] J Biol Chem. 2009 Feb 20;284(8):5030-41 [19098288.001]
  • [Cites] Neurosci Lett. 2008 Jan 31;431(2):141-5 [18191026.001]
  • [Cites] Cell. 2001 Jun 1;105(5):645-55 [11389834.001]
  • [Cites] Hum Mutat. 2000 Jul;16(1):89-90 [10874314.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):274-8 [18301241.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2809-17 [12857866.001]
  • [Cites] EMBO J. 2009 Feb 18;28(4):372-82 [19153604.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Feb;66(2):152-7 [17279000.001]
  • [Cites] Arch Neurol. 2008 Aug;65(8):1031-8 [18695053.001]
  • [Cites] FASEB J. 2008 Nov;22(11):3785-94 [18632848.001]
  • [Cites] Hum Mol Genet. 2008 Mar 15;17(6):906-17 [18065497.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1793-805 [17456782.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5500-5 [15064394.001]
  • [Cites] J Neurosci. 2008 Dec 3;28(49):13285-95 [19052220.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2410-20 [16921029.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000382 [19214209.001]
  • [Cites] Hum Mol Genet. 2001 May 15;10(11):1201-13 [11371513.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10094-104 [19074875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2439-44 [10051661.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38851-61 [16157591.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(22):7955-65 [17875940.001]
  • [Cites] J Alzheimers Dis. 2009;17(2):319-25 [19363271.001]
  • [Cites] J Biol Chem. 2009 Apr 10;284(15):9796-803 [19218238.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):1-7 [16278683.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(8):1384-94 [19168853.001]
  • [Cites] Hum Mol Genet. 2008 Oct 15;17(20):3223-35 [18658163.001]
  • [Cites] Trends Cell Biol. 2002 May;12(5):216-21 [12062168.001]
  • [Cites] Nature. 2005 Nov 10;438(7065):224-8 [16227972.001]
  • [Cites] Neurobiol Dis. 2009 Jul;35(1):32-41 [19348945.001]
  • [Cites] Nat Struct Mol Biol. 2008 Dec;15(12):1334-42 [19043414.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):142-8 [10663629.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jun 5;383(3):331-5 [19358826.001]
  • [Cites] Cell Signal. 2007 Mar;19(3):573-81 [17005371.001]
  • [Cites] Biochem J. 2009 Mar 15;418(3):643-50 [19049493.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1545-52 [8666912.001]
  • [Cites] Eur J Neurol. 2008 Aug;15(8):772-80 [18684309.001]
  • [Cites] Methods Enzymol. 2005;399:334-55 [16338367.001]
  • [Cites] Mol Cell. 2009 May 15;34(3):259-69 [19450525.001]
  • [Cites] Acta Neuropathol. 2008 Aug;116(2):147-57 [18536926.001]
  • [Cites] Drug News Perspect. 2007 Jul-Aug;20(6):365-70 [17925890.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000383 [19214206.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3103-11 [15126347.001]
  • [Cites] J Neurochem. 2008 Jul;106(1):107-20 [18346206.001]
  • [Cites] Autophagy. 2008 Apr;4(3):372-4 [18216494.001]
  • [Cites] Biochemistry. 2007 Dec 25;46(51):14889-98 [18044963.001]
  • [Cites] J Pathol. 2003 Feb;199(2):259-66 [12533840.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11339-46 [8626687.001]
  • [Cites] Neuron. 2003 Jul 17;39(2):217-25 [12873380.001]
  • [Cites] J Neurochem. 2004 Jul;90(2):379-91 [15228595.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Oct;66(10):884-91 [17917582.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):420-6 [10786809.001]
  • [Cites] Science. 2002 Jul 19;297(5580):365-9 [12130776.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):358-66 [11988738.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14(8):1049-58 [15757975.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):3250-63 [19033443.001]
  • [Cites] Mol Cell Biol. 2005 Apr;25(7):2795-807 [15767683.001]
  • [Cites] FEBS J. 2009 Mar;276(5):1208-20 [19175675.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15690-5 [18836078.001]
  • [Cites] ScientificWorldJournal. 2008;8:421-33 [18454252.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):639-46 [18936941.001]
  • [Cites] J Biol Chem. 1982 Mar 10;257(5):2543-8 [6277905.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):28530-6 [12032152.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Exp Neurol. 2007 Feb;203(2):531-41 [17097639.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):61-70 [9427741.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):799-812 [12791266.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):32026-34 [16040601.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2897-902 [19196961.001]
  • [Cites] Eur J Neurosci. 2008 Nov;28(10):1980-8 [19046380.001]
  • [Cites] Mol Cell Proteomics. 2008 Nov;7(11):2107-22 [18565875.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4606-18 [16914519.001]
  • [Cites] Cell. 2009 May 15;137(4):609-22 [19450511.001]
  • [Cites] J Immunol. 1995 Oct 15;155(8):3750-8 [7561079.001]
  • [Cites] Nature. 2007 Aug 9;448(7154):704-8 [17687326.001]
  • [Cites] Science. 2001 Oct 5;294(5540):173-7 [11533444.001]
  • [Cites] Mol Cell Neurosci. 2002 Jun;20(2):298-306 [12093161.001]
  • [Cites] Mol Cell Biol. 2008 Sep;28(17):5275-87 [18573876.001]
  • [Cites] J Cell Biol. 2003 Oct 13;163(1):27-33 [14557245.001]
  • [Cites] Neuron. 2004 Nov 18;44(4):601-7 [15541309.001]
  • [Cites] J Neurosci. 2008 Jul 2;28(27):6926-37 [18596167.001]
  • [Cites] Genes Dev. 2006 Sep 15;20(18):2539-51 [16980583.001]
  • [Cites] J Clin Invest. 2009 Mar;119(3):650-60 [19229105.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1129-42 [17229889.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16041-6 [14668431.001]
  • [Cites] J Biol Chem. 2009 Mar 20;284(12):8083-92 [19112176.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):930-9 [19372566.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):625-37